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Summary 
 
The introduction of combination antiretroviral therapy (cART) in 1996 dramatically reduced the 
morbidity and mortality of HIV-infected patients. Despite these advances in drug development, there 
is no cure for HIV infection and HIV is now considered a chronic illness requiring life-long treatment. 
Standard treatment with cART consists of at least three drugs from two classes and the goal of 
treatment is the continuous suppression of viral replication to undetectable levels. For most 
patients, viral suppression will be achieved within several months of treatment initiation. Although 
adherence is not the only determinant of treatment success, it remains one of the only modifiable 
factors. Chapter 1 of this dissertation gives an introduction into HIV, cART, and non-adherence. 
Chapter 2 describes the goals and objectives of the research. 
Adherence research intensified in early 2000 when results of a study indicated that patients need to 
take more than 95% of their drugs in order to remain virally suppressed. In 2003, the collection of 
adherence information by interview was included in the standard follow-up of patients registered in 
the Swiss HIV Cohort Study (SHCS), a nationwide study including over half of HIV-infected patients in 
Switzerland. Chapter 3 describes the SHCS adherence questionnaire (SHCS-AQ) and methodological 
issues concerning its validity.  
Factors affecting adherence have been described as stemming from five intersecting dimensions. In 
Chapter 4, the first exploration of the SHCS-AQ is carried out and correlates of non-adherence from 
all five dimensions are identified. Of individuals on therapy for at least 6 months, missing one or 
more doses of cART was reported by 31.1% and 5.8% missed more than one dose of cART in a row.  
Irrespective of how non-adherence was defined, factors associated with increased odds of non-
adherence were younger age, living alone, treatment with a higher number of prior regimens, and 
being on a boosted protease inhibitor (PI) regimen compared to being on a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) regimen. We found significant variation in non-adherence by centers 
where the patients receive care, a possible proxy for differences in the system of care across centers.  
Adherence is a dynamic process affected by a variety of factors that can also change over time. One 
of the strengths of the SHCS is the continuous collection of a comprehensive set of information 
about participating HIV-infected patients. In Chapter 5, we use novel approaches to assess patterns 
of adherence and model changes in adherence behavior.  Starting injecting drug use (IDU), 
increasing alcohol intake, becoming depressed, loss of social support (losing a roommate or changing 
clinician or center of care) and onset of lipodystrophy were predictive of worsening adherence. 
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Regimen simplification and changing class of cART predicted improvements in adherence. This study 
highlights how short-term changes in a patient’s circumstances can lead to changes in adherence, 
stressing the importance of continuously monitoring these risk factors.  
Chapter 6 explores the predictive value of self-reported non-adherence on viral rebound using a 
time-dependent Cox proportional hazards models. Time to treatment failure was assessed in 
suppressed patients on cART. We detected a dose-response relationship between the number of 
missed doses and the risk of viral rebound. Additionally, an interaction between dosing frequency 
and non-adherence was found with those on a once-daily regimen being at higher risk of viral 
rebound than those on twice-daily regimens with the same level of non-adherence.  Patients with 
missing adherence information were more likely to experience viral rebound emphasizing the role of 
regular follow-up.  
The last two chapters introduce the concept of causal modeling, which attempts to replicate the 
results of clinical trials using observational data. Chapter 7 introduces the theory behind this 
modeling.  In Chapter 8, marginal structural models are constructed to estimate the causal effect of 
non-adherence on viral rebound and mortality in naïve patients initiating cART. Patient’s missing 2 or 
more doses of cART were 3.6 times more likely to fail treatment and 3.9 times more likely to die 
compared to those with perfect adherence. We could further confirm our exploratory findings from 
the previous study indicating that the impact of non-adherence varies by dosing frequency with 
patients on once daily regimens being at higher risk of poor clinical outcomes than patients on twice-
daily regimens.  
Taken together, these studies provide a validation of a simple self-report adherence questionnaire 
for use in predicting important clinical outcomes in HIV-infected patients. The results highlight the 
importance of continuous and consistent monitoring of drug adherence as well as risk factors for 
non-adherence.  
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Zusammenfassung 
Die Verfügbarkeit wirksamer antiretroviraler Kombinationstherapien (im Englischen combination 
antiretroviral therapy, cART) seit dem Jahr 1996 hat die Morbidität und Mortalität HIV-infizierter 
Patienten dramatisch gesenkt. Trotz dieser Fortschritte in der Arzneimittelentwicklung gibt es bis 
heute keine Heilung  bei einer HIV-Infektion. Diese entspricht jetzt mehr einer chronischen, 
lebenslang behandlungsbedürftigen Erkrankung. Die cART besteht in der Regel aus mindestens 3 
antiretroviralen Substanzen zweier unterschiedlicher Klassen. Ziel der HIV-Therapie ist es, die 
Virusreplikation weitestgehend zu hemmen und die HI-Viruslast wenn möglich unter die 
Nachweisgrenze zu bringen. Die meisten Patienten erreichen dieses Ziel innerhalb weniger Monate 
nach Behandlungsbeginn. Eine gute Therapie-Treue, auch Compliance oder Adhärenz genannt, ist 
gewiss nicht der einzige Einflussfaktor für den Behandlungserfolg, sie bleibt jedoch einer der 
wenigen modifizierbaren Faktoren. In Kapitel 1 dieser Dissertation wird eine Einführung in HIV, cART 
und die Problematik der mangelnden Adhärenz gegeben. Kapitel 2 beschreibt die Zielsetzungen der 
vorliegenden Arbeit. 
Der Bereich Adhärenz findet als wichtiges Element in der Betreuung HIV-infizierter Patienten seit 
einigen Jahren zunehmend Beachtung. Anfang 2000 zeigten die Ergebnisse einer Studie, dass 
Patienten mehr als 95 % ihrer Medikamente korrekt einnehmen müssten, um einen erneuten 
Anstieg der HI-Viruslast nachhaltig zu vermeiden. Im Jahr 2003 wurde die Erhebung von Merkmalen, 
die Aufschluss über die Adhärenz eines Patienten geben, in die Schweizerische HIV-Kohortenstudie 
(Swiss HIV Cohort Study, SHCS), eine landesweite Studie, die über die Hälfte der HIV-infizierten 
Patienten in der Schweiz einschliesst, eingeführt. Dazu wird im Rahmen der regelmässigen 
Verlaufskontrollen der in die Studie eingeschlossenen Patienten eine mündliche Befragung 
durchgeführt. In Kapitel 3 wird der Fragebogen der SHCS zur Adhärenz (im Englischen SHCS 
adherence questionnaire, SHCS-AQ) vorgestellt und es werden methodologische Probleme in Bezug 
auf dessen Validität diskutiert. 
Die in der Literatur für die korrekte Einnahme der Therapie beschriebenen Einflussgrössen können 
grob in fünf sich überschneidende Bereiche unterteilt werden. In Kapitel 4 der vorliegenden Arbeit 
wird der SHCS-AQ zunächst explorativ untersucht und weiter eine Zusammenhangsanalyse der 
mangelnden Adhärenz mit Merkmalen aus allen fünf Bereichen durchgeführt. Für Patienten, die 
während mindestens sechs Monaten eine medikamentöse Therapie erhalten haben, ergab sich eine 
Nicht-Adhärenzrate im Sinne einer unregelmässigen Medikamenteneinnahme, d.h. eine oder 
mehrere versäumte Einnahmen, von 31.1%. Die selbst deklarierte Nicht-Adhärenzrate im Sinne von 
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mehr als einer in Folge versäumten Dosis lag bei 5.8%. Unabhängig von der gewählten präzisen 
Definition mangelnder Adhärenz ergab sich, dass jugendlicheres Alter, alleine leben, die Anzahl 
vorausgegangener Umstellungen in der medikamentösen HIV-Therapie und das Therapieregimen mit 
einem „geboosterten“ Protease-Inhibitor (PI) im Vergleich zu einem nichtnukleosidischen Reverse-
Transkriptase-Inhibitor (NNRTI) Faktoren sind, die die Chancen für Nicht-Adhärenz erhöhen. Die 
Analysen zeigen ausserdem eine deutliche Variabilität der Nicht-Adhärenz über die verschiedenen 
Zentren, in denen die Patienten betreut werden. Dies kann eventuell als Indiz für Unterschiede im 
Betreuungsangebot der verschiedenen Zentren gesehen werden. 
Die Adhärenz entwickelt sich dynamisch und wird von einer Vielzahl Faktoren, die sich über die Zeit 
ändern können, beeinflusst. Die regelmässige Erhebung verschiedenartiger Merkmale für die in die 
Studie eingeschlossenen HIV-infizierten Patienten ist eine der Stärken der SHCS. In Kapitel 5 werden 
neuartige Verfahren zur Erkennung bestimmter Muster im Adhärenz-Verhalten angewendet und 
Änderungen modelliert. Als Risikofaktoren für eine Verschlechterung der Adhärenz ergaben sich 
beginnender intravenöser Drogenkonsum, zunehmender Alkoholkonsum, das Auftreten von 
Depressionen, der Verlust sozialen Rückhalts (d.h. Verlust eines Partners / Mitbewohners oder 
Wechsel des betreuenden Arztes bzw. Studienzentrums) und die Diagnose von Lipodystrophie. Die 
Vereinfachung des Therapieregimens und Umstellung auf eine andere cART-Klasse prognostizierten 
eine Verbesserung im Adhärenz-Verhalten. Aus der vorliegenden Untersuchung ergibt sich, dass 
kurzfristige Veränderungen der persönlichen Lebenssituation und des individuellen Therapieschemas 
die korrekte Einnahme der HIV-Therapie beeinflussen können. Demzufolge kommt der stetigen 
Beobachtung der oben genannten Risiko- und prognostischen Faktoren eine besondere Bedeutung 
zu. 
Kapitel 6 ist der Untersuchung des prognostischen Wertes selbst deklarierter mangelnder Adhärenz 
für einen erneuten Anstieg der HI-Viruslast gewidmet. Dazu wurde ein Cox-Modell mit 
zeitabhängigen Kovariablen angepasst, um die Zeit bis zum Therapie-Versagen bei  Patienten, die 
eine cART erhalten und bei denen die Virusreplikation anfangs erfolgreich unterdrückt werden 
konnte, zu untersuchen. Die Resultate zeigen eine Dosis-Wirkungs-Beziehung zwischen der Anzahl 
versäumter Einnahmen und dem Risiko für einen erneuten Anstieg der Viruslast auf. Ausserdem 
ergab sich eine signifikante Wechselwirkung zwischen der Einnahmehäufigkeit und mangelnder 
Adhärenz, wobei Patienten mit antiretroviralen Therapieregimen mit einer Medikamenteneinnahme 
alle 24h ein höheres Risiko für einen erneuten Anstieg der Viruslast hatten als Patienten mit 
ähnlicher Nicht-Adhärenz und einem Therapieregimen mit einer Einnahme alle 12h. Überdies zeigten 
Patienten, für die keine Angaben zur individuellen Therapie-Treue verfügbar waren, ein erhöhtes 
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Risiko für Therapieversagen. Dies unterstreicht nochmals die Wichtigkeit, auf persönliche 
Lebensumstände zu Beginn der Behandlung einzugehen und den Therapieverlauf nachhaltig zu 
beobachten. 
In den letzten beiden Kapiteln dieser Arbeit werden statistische Verfahren der kausalen 
Modellierung vorgestellt. Die zugrunde liegende Idee ist, basierend auf Daten aus 
Beobachtungsstudien die  Ergebnisse und Ausgangslage kontrollierter klinischer Studien 
nachzuempfinden. Kapitel 7 gibt eine Einführung in die zugrunde liegende Theorie. In Kapitel 8 
werden so genannte „Marginal Structural Models“ angepasst, um den kausalen Effekt mangelnder 
Adhärenz bei HIV-Infizierten, die eine antiretrovirale Initialtherapie beginnen, auf einen erneuten 
Anstieg der Viruslast und das Risiko zu sterben zu untersuchen. Im Vergleich zu Patienten mit sehr 
guter Therapie-Treue war die Chance für Therapieversagen für Patienten, die mindestens 2 
Einnahmen ihres cART-Regimens versäumt hatten, um den Faktor 3.6, die Chance zu sterben um den 
Faktor 3.9 erhöht. Des Weiteren konnten die Resultate der vorigen Zusammenhangsanalyse 
bestätigt werden, dass der Effekt mangelnder Adhärenz von der vorgeschriebenen 
Einnahmehäufigkeit des individuellen Therapieregimens abhängt. Die einmal täglich vorgeschriebene 
Medikamenteneinnahme birgt bei vergleichbarer Adhärenz ein höheres Risiko für ein ungünstigeres 
klinisches Ergebnis als die zweimal täglich vorgeschriebene Einnahme. 
Die Untersuchungen der vorliegenden Arbeit validieren den Fragenbogen zur selbst deklarierten 
Adhärenz HIV-infizierter Patienten unter cART und seine Verwendung für die Vorhersage wichtiger 
klinischer Zielgrössen. Die Resultate zeigen die zentrale Bedeutung auf, die der fortdauernden und 
beständigen Überwachung der Adhärenz und relevanter Risikofaktoren für eine Verschlechterung 
der Adhärenz zukommt. 
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Chapter 1: Introduction 
1. The HIV epidemic 
Human immunodeficiency virus (HIV) is the cause of acquired immunodeficiency syndrome (AIDS) 
and has killed more than 25 million people since its discovery in 1981 in the US. The global spread of 
HIV appears to have peaked in 1996, when 3.5 million new infections occurred [1]. In 2008, an 
estimated 33.4 million people were living with HIV, 2.7 million adults and children were newly 
infected, and there were 2.0 million AIDS-related deaths (Figure 1.1).  
 
Figure 1.1 Estimate of global HIV-1 epidemic.  Adapted from [1]. 
 
 
In high income countries, the number of new infections has either stabilized or increased slightly in 
recent years.  However, the epidemic is evolving over time and in the past decade there has been a 
rising number of new infections in men having sex with men (MSM) paired with a decrease in new 
infections among injecting drug users (IDU).  
In Switzerland there are an estimated 25,000 people living with HIV [1] and approximately 750-800 
individuals are newly infected every year [2]. Following the decrease in HIV infections between 1992 
and 2000, there was a 25% increase in new infections reported in 2002, mainly in Swiss MSM and 
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heterosexuals originating from countries with a high HIV prevalence [3]. Since 2002 the trend has 
stabilized, however the percentage of new infections have continued to increase in MSM with a 
corresponding decrease in the other transmission groups, particularly among heterosexuals. IDU 
went from being the primary mode of transmission for new HIV diagnoses in the late 1980’s to 
accounting for only 4% of new infections in 2008 (Figure 1.2).  
 
Figure 1.2 Time trends in mode of HIV infection in Switzerland. Adapted from [3]. 
 
 
2. Classification of HIV 
There are two species of HIV known to exist, HIV-1 and HIV-2. Both types of the virus are believed to 
have originated in West-Central Africa by transfection from non-human primates to humans. The 
HIV-1 subtype genome closely resembles lentiviruses that are derived from chimpanzees in southern 
Cameroon. HIV-1 is the cause of most infections globally and is both more virulent and more 
infective [4] than HIV-2, which is largely confined to West Africa due to its relatively poor capacity for 
transmission [5].  
HIV-1 is further classified into 10 main subtypes and specific subtypes dominate the epidemic in 
different regions of the world [6]. The most frequently observed subtype is C, which accounts for 
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over 50% of all HIV infections worldwide and is found predominantly in Africa and India. The second 
largest subtype is A, which is common in Eastern Europe, and certain parts of East and West Africa. 
Subtype B is the most prevalent subtype in North America, Western Europe, and Australia and 
constitutes around 10% of all HIV-1 infections. Drug development for HIV often focuses on this 
subtype despite its relatively low frequency. The additional subtypes, from D to K, make up less than 
5% of HIV-1 infections. In Switzerland the vast majority of HIV infections are subtype B, however the 
presence of other subgroups, such as A, C, and CRF_01, are growing [7] largely due to the migration 
of infected patients or infections acquired abroad [8].  
3. The natural course of HIV-1 infection 
HIV-1 is a lentivirus (a member of the retrovirus family) that infects particular vital cells of the 
immune system, such as helper T cells (specifically CD4+ T cells), macrophages, dendritic cells and 
microglia cells. HIV-1 entry into macrophages and CD4+ T cells is mediated through the interaction of 
the virion envelope glycoproteins (gp120) with the CD4 molecule on the target cells and also with 
chemokine co-receptors. Macrophage (M-tropic) strains of HIV-1, or non-syncitia-inducing strains 
use the β-chemokine receptor CCR5 for entry and are thus able to replicate in macrophages and 
CD4+ T cells. This CCR5 co-receptor is used by almost all primary HIV-1 isolates regardless of viral 
genetic subtype. Macrophages play a key role in several critical aspects of HIV infection and are the 
first cells infected by HIV. Macrophages and microglial cells are the cells infected by HIV in the 
central nervous system. In tonsils and adenoids of HIV-infected patients, macrophages fuse into 
multinucleated giant cells that produce large amounts of virus. T-tropic isolates, or syncitia-inducing 
strains replicate in primary CD4+ T cells as well as in macrophages and use the α-chemokine 
receptor, CXCR4, for entry.  Dual-tropic HIV-1 strains are thought to be transitional strains of the 
HIV-1 virus and thus are able to use both CCR5 and CXCR4 as co-receptors for viral entry. 
Infection with HIV occurs through transfer of blood, semen, vaginal fluid, and breast milk. The most 
common routes of transmission are sexual intercourse or needle sharing among IDU. Mother-to-
child transmission has been virtually eliminated in high income countries due to pre-delivery HIV 
testing, antiretroviral transmission prophylaxis, and elective cesarean section [9,10], but it is still 
common in resource-limited countries.  
When CD4 cells decline below a critical level, cell-mediated immunity is lost and the body becomes 
progressively more susceptible to opportunistic infections or HIV related non-Hodgkin lymphoma.  
The most advanced stage of HIV infection is AIDS. The rate of progression from HIV to AIDS varies 
according to host, viral, and environmental factors. Although HIV-specific treatment delays 
progression, most individuals develop AIDS within 10 years of infection [11,12].  
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HIV-1 infection has four stages: incubation, acute infection, chronic infection, and AIDS (Figure 1.3). 
The incubation period usually lasts only 2-4 weeks and is asymptomatic. The acute phase starts with 
infection and lasts an average of 28 days with around 50-70% of individuals experiencing a wide 
range of unspecific symptoms such as fever, swollen lymph nodes, sore throat, muscle pain and rash 
[13]. Antibodies against HIV typically develop within 3 to 6 months after infection. During this phase, 
there is massive viral replication leading to a sharp increase in HIV-1 RNA levels often approaching 
several million copies per ml. At the same time, there is a plunge in CD4 cell counts. As HIV-1 specific 
immune responses develop, HIV-1 RNA levels decrease and CD4 cells recover, but not to pre-
infection levels.  In particular, HIV-1 RNA declines to a viral set point, defined as the relatively stable 
level observed during the chronic infection phase. The viral set point is highly variable between 
patients and is determined by both host and viral factors [14].  The chronic phase is characterized by 
a relatively symptom-free period and can last anywhere from 2 weeks to 20 years.  Viral load 
remains at the viral set point but there is a gradual decline in CD4 cell counts over time. When CD4 
cell counts decline below a critical level of 200 cells per μL, an individual is considered to have 
entered the last stage of infection, AIDS. During this stage, cell immunity is lost and the individual 
becomes susceptible to opportunistic infections or other AIDS-defining illnesses, which are 
eventually fatal.  
 
Figure 1.3 Stages of HIV infection. Adapted from [15]. 
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4. Treatment for HIV 
There is currently no cure or vaccine for HIV or AIDS and treatment consists of antiretroviral therapy 
(ART) [16]. The basic principle of antiretroviral therapy is immune restoration by achieving a maximal 
recovery of CD4 cells with permanent and sustained virologic suppression. There are different 
classes of antiretroviral drugs each targeting specific stages of the HIV life-cycle [17,18] (Figure 1.4).  
Development of antiretroviral therapy 
Nucleoside reverse transcriptase inhibitors (NRTI), the first and most established class of 
antiretroviral drugs, target the life cycle at the reverse transcription stage where single-stranded 
RNA is converted into a double-stranded DNA. NRTIs prevent completion of DNA synthesis, and thus 
prevent HIV from multiplying.  In 1987, the NRTI zidovudine (AZT) became the first FDA-approved 
drug for the treatment of HIV infection [19] followed a few years later by didanosine, zalcitabine, 
lamivudine and stavudine.  The process of reverse transcription is extremely error-prone and it is 
during this step that mutations may occur. Therefore the clinical benefits of monotherapy with AZT 
were limited [20] due to the rapid emergence of drug resistance strains [21].  
In 1996, protease inhibitors (PI) became the second drug class available to treat HIV infection. PIs 
target the last stage of the life cycle, maturation. After viral particles are released from the host cell 
they must undergo maturation in order for the viral particle to become infectious. Shortly after the 
introduction of PIs such as saquinavir, ritonavir, indinavir, and nelfinavir, clinical studies showed that 
combination treatment with more than one drug class resulted in a significantly prolonged benefit 
compared to NRTI-based mono- and dual therapy [22,23]. As a result, guidelines for the treatment of 
HIV were updated in 1997 [24] to prescribe ART as a combination of three drugs from two different 
classes (2 NRTI with 1 PI).  
In 1998, non-nucleoside reverse transcriptase inhibitors (NNRTI), specifically nevirapine and 
efavirenz, were developed to target the reverse transcription stage, similar to NRTIs. They were soon 
found to be a very potent class of drugs with a long half life allowing for once daily administration 
[25,26]. In particular, nevirapine was found to have similar potency compared to either a PI or NRTI 
regimen [24].  Efavirenz exhibited better or equal potency when compared to ritonavir boosted PIs 
[27].   
A further milestone in ART development was the concept of ritonavir-boosting, which dramatically 
increases the bioavailability of most PIs except nelfinavir [28]. Compared to unboosted PIs, newer 
combinations of boosted PIs or NNRTIs have a lower viral failure rate [26,29] as well as being more 
tolerable and having a lower pill burden.  
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Figure 1.4 HIV replication cycle. Reproduced from [16]. 
 
 
 
In antiretroviral naïve patients, current guidelines suggest drug combinations consisting of at least 
three drugs belonging to at least two classes, typically two NRTIs plus either a PI or a NNRTI [30,31]. 
At present four ritonavir boosted PIs and two NNRTIs are licensed and recommended for the 
treatment of drug naïve patients.  Figure 1.5 gives an overview on trends in antiretroviral therapy 
use in the Swiss HIV Cohort Study (SHCS), a national cohort of HIV-infected individuals in 
Switzerland.  
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Figure 1.5 Trends in antiretroviral therapy use in the Swiss HIV Cohort Study 
 
 
New classes of drugs have been introduced in recent years that at present are primarily reserved for 
patients with advanced HIV infection with multiple drug resistance to first line antiretroviral drugs. In 
2003, fusion inhibitors, designed to intervene at the very first step of the life cycle with the entry of 
the virus into the host cell, became the first class of these salvage drugs and were found to be 
effective in treatment experienced patients [32]. In the last five years, remarkable improvements for 
the treatment of patients with advanced multi-resistant HIV infection were seen with the 
introduction of the PIs darunavir and tipranavir and the NNRTI etravirine [33-35]. In 2008, two new 
drugs were approved for treatment experienced patients. Raltegravir was the first approved 
integrase inhibitor, designed to block the action of integrase, which is a viral enzyme that inserts the 
viral genome into the DNA of the host cell. Integration is a vital step in retroviral replication so 
blocking it can halt further spread of the virus. Maraviroc was the first approved CCR5 inhibitor, 
blocking the entry of the virus into the host cell, similar to fusion inhibitors. Both drugs have shown 
promising results in multi-drug resistant HIV infection and improved surrogate marker outcomes 
when compared to optimized ART [36-38]. However, these drugs are not yet widely available 
especially in resource-limited countries. 
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Impact of combined antiretroviral therapy 
The introduction of combination antiretroviral therapy (cART) in 1996 has lead to a dramatic 
reduction in hospitalization rates, opportunistic infections, and deaths associated with HIV infection 
[39-41]. In particular in Switzerland, the number of AIDS-related deaths has decreased dramatically 
from more than 600 in 1995 to less than 50 in 2008 [3]. In high-income countries, the life expectancy 
of a 20-year old individual starting cART has risen from 36.1 to 49.4 years between 1996 and 2005 
[42]. Without cART, median survival after developing AIDS is only 9.2 months [43] compared to more 
than 5 years with cART [44]. Even when taking cART, treatment failure can occur due to a variety of 
reasons such as medication intolerance or infection with a drug-resistant strain of HIV. With modern 
antiretroviral therapy 90% of patients from an unselected population may be expected to achieve 
sustained virologic suppression and a satisfactory immune restoration [45].  It may well be expected 
that prognosis of HIV-infected patients receiving antiretroviral therapy will further improve in the 
future.  
Factors associated with poor outcome in patients receiving cART  
In observational studies and clinical trials several factors have been associated with surrogate 
markers of HIV infection (CD4 cell count and HIV-1 viral load) and clinical endpoints (AIDS or death). 
Initiating cART at a late stage, with CD4 cells below 200 cells per µL, is associated with worse clinical 
outcomes [46].  The question as to whether one should initiate cART at CD4 cell counts > 350 cells 
per µL or higher rather than deferring the start of cART is currently the subject of debate and under 
investigation in a large clinical trial.  Preliminary evidence from observational studies indicates a 
lower risk of AIDS and deaths in patients initiating cART at higher CD4 cells compared to individuals 
with deferred initiation of cART [47,48]. In prospective cohort studies IDU was found to be related to 
worse immune restoration, higher risk of virologic failure and increased risk of death from AIDS and 
non AIDS-related conditions [49], although a recent study did not find increased mortality in this 
patient group [50]. Age was shown to be related to worse CD4 cell recovery [51,52]. Several studies 
have shown improved outcomes of HIV surrogate markers in females compared to males [53]. Co-
infection with hepatitis B and C has been shown to be associated with compromised immune 
recovery and increased risk of death from liver disease when compared to non co-infected 
individuals [54,55].  In several observational studies non-adherence to cART was found to be 
associated with increased risk of virologic failure, acquisition of HIV drug resistance, and progression 
to AIDS [56-59]. 
 
 19 
5. Adherence to antiretroviral therapy 
According to the World Health Organization (WHO), adherence is defined as “the extent to which a 
person’s behavior – taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider” [60]. The importance of 
adherence to cART has increased as treatment of HIV currently requires life-long therapy once 
initiated in order to maintain maximal viral suppression and to avoid drug failure and the emergence 
of resistance to HIV drugs. Compared to continuous treatment with cART, treatment interruptions, 
including medically guided ones, increase the risk of opportunistic disease or death from any cause 
largely as a consequence of increasing viral load and lowering CD4 cell count, resulting in suboptimal 
CD4 cell recovery once cART is reinitiated [46]. Long-term viral suppression requires very high if not 
perfect adherence [61]. Virologic failure not only reduces future treatment options and therefore 
long-term clinical success but also increases the possibility of developing drug resistant mutations 
[62,63].  Drug-resistant strains of HIV can then be transmitted to uninfected or drug-naïve individuals 
limiting their future treatment options [64], making adherence an important public-health topic.  
Despite the serious consequences of non-adherence, the reported percentage of prescribed doses 
taken in the United States and Europe ranges from 60-70% [65]. Although adherence is not the only 
determinant of treatment success, it remains one of the only modifiable factors. However, health 
care providers have proven to be poor at assessing and improving adherence in patients [66,67]. 
Adherence continues to be a challenging and complicated topic that requires a commitment from 
both the patient and the health care team. 
 
Measuring adherence 
Adherence is a dynamic process and has been shown to vary over time [68-72]. Therefore adherence 
should be monitored and measured regularly as a part of routine clinical care. However, there is no 
gold standard for the assessment of adherence nor is there a single optimal tool that enhances 
adherence to HIV/AIDS treatment regimens [73]. Each method described below has its own 
strengths and weaknesses and therefore the choice of measurement method often depends on the 
purpose and intended use of the measurement. 
When focusing on the behavioral dimension of adherence to cART, four dimensions of adherence 
merit consideration: taking adherence (the extent to which a patient is taking the prescribed 
medication), timing adherence (the extent to which a patient is adhering to the prescribed schedule 
for drug intake), drug holidays (missing several doses of medication in a row), and food restrictions 
(the extent a patient is adhering to drug intake in relation to food restrictions) [60].  
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Microelectronic Monitoring System 
Microelectronic Monitoring Systems (MEMS) utilizes a computer chip embedded in a specially 
designed pill-bottle cap to record the time and duration of each opening of the bottle. MEMS can 
measure all the dimensions of adherence except food restrictions. However, the number of pills 
taken from the bottle at each opening is unknown and therefore additional doses withdrawn to be 
taken at another time (so called ‘pocket doses’) will not be recorded.  In a study by Bova et al, 41% of 
patients reported pocket doses and 26% reported opening the pill bottle without removing any 
doses suggesting MEMS can lead to an underestimate of adherence [74]. This also prohibits the use 
of MEMS caps in conjunction with other adherence support devices, such as pill boxes, where large 
quantities of pills are withdrawn at one time. In addition, MEMS is normally used to monitor only 
one medication in the regimen, therefore adherence to the other drugs is not measured. However 
one study indicated that the adherence for one drug may be a good indicator of the adherence for 
the entire regimen [75].  
Although MEMS cap has been shown to be the most sensitive measure of adherence [76,77] and is 
associated with treatment failure [78-81], its use has been primarily limited to research settings. In 
addition to the limitations listed above, MEMS caps are expensive making widespread use, especially 
in resource-limited settings, prohibitive.   
Prescription refill  
Prescription refill data is constructed from the dates when medications were dispensed to an 
individual by the pharmacy.  If the prescription is not refilled within the supply period of the 
prescription, it is assumed that the individual has missed doses during this time. This assumption 
does not allow for the possibility that the individual received additional medication from other 
sources or had a stockpile of medication at home due to missed doses during other periods of time. 
In addition, prescription refill measures only the taking adherence dimension as the timing of the 
missed doses and drug holidays, as well as violation of food restriction, during the supply period is 
unknown.  
There are also feasibility issues with regards to data collection. Information might be missed if 
individuals are not required to fill their prescriptions at one particular pharmacy. Or the data may 
not be accessible due to privacy laws. Despite these challenges, pharmacy refill data has been shown 
to be associated with viral suppression, resistance, and progression to AIDS and death [57,82-84]. 
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Pill counts 
Pill counts only measure taking adherence and can be conducted during clinical visits or at home 
during either announced or unannounced visits. If the pill count is scheduled, patients may discard 
missed doses (so called ‘pill dumping’) prior to the visit. Unannounced pill counts, however, have 
been found to be associated with virologic failure [85], development of resistance [62,86], and 
progression to AIDS [59]. Despite this, unannounced pill counts are too intrusive and labor intensive 
for widespread use in clinical practice. 
Biologic markers 
The most commonly used biological marker for adherence is plasma drug concentrations with pre-
dose drug concentrations lower than the limit of detection considered an indicator of non-
adherence. Use of drug concentrations to measure adherence has the limitation that only recent 
taking adherence behavior is measured. In addition, there can be other reasons why drug 
concentration levels are lower than expected, such as individual genetic or metabolic differences, 
malabsorption, or drug interactions. 
Several studies have shown biologic markers to be associated with adherence measured by self-
report [87], unannounced pill counts [88], and MEMS caps [89]. Another study also reported an 
association between biologic markers and viral load [90].   
Self-report 
Self-report is by far the simplest and most convenient method of measuring adherence. It is also 
extremely flexible and can measure all four dimensions of adherence behavior. However, it is subject 
to recall bias, social desirability bias (patient’s desire to be seen as a ‘good patient’) and discomfort 
in disclosing non-adherent behavior [91]. While patients’ reporting of non-adherence has been 
found to be credible [76], their estimate of adherence is often inaccurate [92,93] overestimating 
adherence by 10-20% compared to MEMS [94,95]. However, the reason for over reporting 
adherence is most often thought to be due to misremembering rather than intentional deception 
although both phenomenon exist in practice [96].  Nonetheless, two systematic reviews including a 
large number of observational studies found a robust association between self-reported adherence 
and viral load over varying measures and recall periods [65] and indicated that self-reported 
adherence measures can distinguish between clinically meaningful patterns of medication-taking 
behaviour [97].  
There exist many different validated self-report instruments for measuring adherence complicating 
the comparability and interpretability of study findings. These instruments differ in length and type 
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of questions, as well as recall periods. Recent evidence suggests that a recall period of 30 days may 
be optimal with less over reporting than 3-7 day recall [65,98,99].  
Factors affecting adherence 
The WHO developed a framework for assessing factors effecting adherence as a means of designing 
interventions to improve adherence [60]. Understanding these factors can increase a clinician’s 
attention to adherence when treating particularly susceptible patients. Factors affecting adherence 
were divided into five intersecting dimensions (Figure 1.6).   
Social/economic-related factors 
In general, sociodemographic factors, such as age, gender, and education, have not been 
consistently associated with adherence. Social support is the exception and patients with supportive 
friends and family tend to adhere better compared to those without such support [100-102]. Studies 
have reported conflicting evidence about the association between many sociodemographic factors 
and adherence [103]. However, when an association was found, the nature of the relationship was 
consistent: older age [72,100,104], white ethnicity [71,72,105], higher education [105,106], higher 
income [71,106] and stable housing [100-102,107] were associated with better adherence.  
 
Figure 1.6 Five dimensions of factors known to affect adherence to medication. Reproduced from 
[108]. 
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Patient-related factors 
The most important variables affecting adherence are patient-related. Even the most effective 
regimen will fail if a patient does not take medication as prescribed. For the most part, patient-
related factors fall under the category of psychosocial variables including substance abuse, mental 
health, and knowledge and attitudes about HIV and its treatment.  Life stress or negative life events 
were found to interfere with the ability to take medications [105,109] and women have cited stress 
of childcare as a reason for missed doses [100,107]. Both active IDU and alcohol consumption are 
highly correlated with non-adherence [100,103,109-112], although it has been shown that a good 
provider-patient relationship can mediate this effect [113]. Psychological distress in the form of 
depression or psychiatric comorbidity has been consistently associated with higher levels of non-
adherence [71,100,103,110,111]. Belief about the effectiveness of cART, understanding the side 
effects of cART, as well as the relationship between adherence and important clinical outcomes, 
have all been found to associated with better adherence [101,103,104,112,114,115]. 
Therapy-related factors  
Therapy or treatment-related factors include regimen complexity (number of pills per day, number 
of doses per day, and dietary restrictions), class of cART, and side effects. Although there has been 
progress in the recent years towards simplification of cART regimens, adherence to HIV medication 
can be extremely complicated and, together with toxicity problems or side effects, can greatly 
influence an individual’s willingness to adhere to therapy. Originally, health professionals believed 
that the number of daily pills in a regimen (or ‘pill burden’) had a strong influence on adherence 
[116].  The number of daily doses in a regimen (or ‘dosing frequency’) has been found to impact 
adherence with those on once or twice-daily regimens exhibiting better adherence than those on 
three-times daily regimens [81,100,106,117]. Other studies have shown that it is more important 
that a regimen fit into the daily routine or lifestyle of the patient [105,112].  
Most cART regimens are potent and usually have both transient side effects such as diarrhea and 
vomiting as well as long-term side effects like lipodystrophy, which can manifest itself as fat 
accumulation or wasting. There is clear evidence that medications producing side effects are 
significant associated with reduced adherence [100,104,112,118,119]. In addition, side effects 
account for more regimen changes than treatment failure [120,121]. D’Arminio and colleagues 
reported that over 25% of treatment naïve patients discontinued therapy in the first year due to 
toxicity [122].  In particular, Kasper et al found that 37% of respondents either stopped or changed 
regimens due to lipodystrophy, which can be a serious long-term side effect.  The actual number of 
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side effects was also found to be important with each additional reported side effect being 
associated with significant increases in non-adherence [111,123].   
Condition-related factors 
Very few studies have examined the effect on adherence of condition or disease-related factors, 
such as stage and duration of HIV infection, opportunistic infections, and HIV-related symptoms. 
Studies assessing clinical stage produced inconsistent results [77,105,119] with only one study 
reporting better adherence in symptomatic patients (CDC-stage B and C disease)[114].  
Health care/system-related factors 
Health care or system-related factors encompass the patient-provider relationship and aspects of 
the clinical setting. The patient-provider relationship includes patient’s overall satisfaction and trust 
in the provider and staff, their perception of provider’s competence, the provider’s willingness to 
include the patient in treatment decisions, and the tone of the relationship. When a patient has a 
meaningful and supportive relationship with their provider they are better able to overcome barriers 
and achieve good adherence [87,101,102,112,114]. However a recent study did not find an 
association between patient confidence in their clinician and adherence [100].  
Important aspects of the clinical setting in high-income countries include confidentiality, previous 
experience with the health care system, and convenience in scheduling appointments. Despite the 
relevance of these factors, they are not well-studied.  Chesney and colleagues found that poor 
previous experience with the health care system was associated with non-adherence [112]. 
Several important system factors affecting adherence in resource-limited settings, such as cost, 
transportation and access, are beyond the scope of this report and not discussed further [124].  
 
Impact of non-adherence 
Treatment failure 
The initial goal of cART - as outlined above - is to attain full and durable viral suppression. Early 
reports in individuals on non-boosted PIs estimated that they must take 95% of their medication to 
remain virally suppressed [81]. This estimate became an informal rule and persisted for many years 
unchallenged and resulted in more attention being focused on adherence monitoring and 
management.  In recent years, several studies were done to explore whether the 95% rule applied to 
other drug classes and found NNRTI and boosted PI regimens to be more ‘forgiving’ – able to achieve 
and maintain viral suppression despite imperfect medication adherence [125-128].  The majority of 
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patients on potent regimens are able to maintain viral suppression at adherence rates lower than 
95% [129-131]. In addition, a recent study found that the level of adherence necessary to achieve 
initial viral suppression is higher than what is necessary to maintain long-term viral suppression, with 
the risk of virologic failure for adherence levels above 50% declining with longer duration of 
continuous viral suppression [85]. 
Adherence has been shown to be associated with viral rebound using a variety of measurement 
tools [78-80,82,83,118,132-135]. In particular, a review found that self-reported adherence was 
significantly correlated with viral load in 84% of comparisons [65]. Nieuwkerk and Oort compiled 65 
studies of self-reported adherence to estimate a pooled odds ratio of having a detectable viral load 
of 2.31 (95% confidence interval (CI): 1.99 – 2.68) in non-adherent patients compared to adherent 
patients [97].  
Resistance 
The initial belief that ‘Non-adherence leads to drug-resistant HIV’ came from experience in multi-
drug resistant tuberculosis, where resistance was seen almost exclusively in individuals at risk for 
non-adherence [136]. This view also shaped public health debates regarding the potential benefits 
and dangers of providing cART to populations at risk for non-adherence [64,137].  
Implications for non-adherence were not just on the individual level as suboptimal adherence could 
lead to resistance which could then be transmitted to others [138]. However, studies of the 
relationship between adherence and resistance in HIV were only conducted a few years ago and 
indicate that the relationship is more complicated than originally thought, with each drug class 
having a unique adherence-resistance relationship [139-142]. 
The adherence-resistance relationship in regimens containing a single PI or NRTI is thought to be 
similar. Studies showed that most drug resistant mutations were occurring in individuals with 
adherence above 90% [62,143,144,144,145]. A subsequent mathematical model determined that 
the maximal resistance occurs at 87% adherence and declines only modestly with perfect adherence 
[146]. This degree of adherence is low enough to allow for viral failure while high enough to exert 
selective pressure for resistant virus.  
Boosted PI regimens (PIs taken with another PI drug, usually ritonavir) allow for more potent viral 
suppression than ritonavir unboosted PIs and this reduces the emergence of resistant mutations. 
Boosting also increases the half-life of the PI and so PI concentrations remain in a suboptimal 
therapeutic range for only a brief time during periods of non-adherence [143]. Resistance to PIs 
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usually requires multiple mutations; therefore high level resistance requires both ongoing viral 
replication and sufficient drug exposure to create a selective advantage for drug-resistant virus [86].  
For NNRTIs, resistance is associated with interruptions in therapy [147] and develops at a lower level 
of adherence than PI resistance [148]. Unlike most PI drugs, resistance to the NNRTIs nevirapine and 
efavirenz requires only a single mutation at the K103N codon and even a single dose of NNRTI 
monotherapy can result in resistance [149]. In addition, NNRTIs have long half-lives allowing the 
virus to replicate in the presence of consecutive missed doses. Resistance mutations are common in 
patients with any level of adherence that is insufficient for full viral suppression but uncommon in 
highly adherent patients. The clinical implications of NNRTI resistance are considerable since NNRTI 
resistance almost universally confers to cross-resistance to first generation NNRTIs and persists in 
most cases even after drug discontinuation [150]. 
This complicated relationship between adherence and resistance and viral suppression makes the 
choice of regimen challenging. The widespread use of NNRTIs could have greater public health 
consequences compared to boosted PIs. However, NNRTIs are less expensive, more potent, easier to 
administer, and more tolerable making them the natural choice for initial regimen especially in 
resource-limited settings.  
AIDS-defining illness and mortality  
A limited number of studies have examined the relationship between non-adherence and mortality 
[56-58] or progression to AIDS [59]. A meta-analysis of the association between adherence and 
mortality found a pooled odds ratio of death in the subset of HIV studies of 0.53 (95% CI: 0.41 -0.69) 
in adherent patients compared to non-adherent patients [151]. However, the findings of these 
studies are difficult to interpret due to confounders such as more advanced stages of HIV infection 
(lower CD4 cell counts at the start of cART), baseline HIV-1 RNA, type of cART (mono, dual, or triple 
therapy), year of initiation of therapy, and depression. In addition, all these studies have 
methodological limitations; either no adjustment for confounding or used only standard statistical 
models to adjust for confounding which can result in biased effect estimates.  
Public health implications of non-adherence to antiretroviral drugs  
The importance of adherence in the life of an HIV-infected person on cART is undisputed. However, 
the adherence patterns of individuals can also have public health implications. As discussed above, 
non-adherent individuals can develop drug resistance and then transmit this drug-resistant virus to 
others. However, after a period of increasing prevalence [152-154], there have been several recent 
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reports of stabilized or decreasing trends in transmitted drug resistant virus in newly infected 
patients [155] as well as treatment experienced patients [156-158].  
In addition, it is thought that individuals with detectable viraemia are more infectious therefore non-
adherence can lead to an increase in overall transmissibility and incidence of HIV. Vernazza and 
colleagues found a strong association between HIV-1 RNA viral load in the plasma with that in the 
seminal and vaginal fluids [159].  Suppressing the serum viral load has been shown to reduce 
mother-to-child transmission [160] and is believed to also reduce the risk of sexual transmission 
[161-164]. There has been some evidence that the introduction of cART led to an increase in risk 
behavior [165-167], therefore the beneficial use of cART in terms of decrease in the risk of 
transmission was thought to be partially negated by the increase in risk behavior [168]. Other studies 
however found stable or decreasing trends in risk behavior [169,170] and a meta-analysis of the 
association between use of cART and sexual risk behavior did not find a significant effect [171]. 
However, a recent randomized controlled trial of continuous versus intermittent cART found an 
increase in the risk of transmission in those with intermittent cART [63]. It remains an open question 
as to whether individuals with undetectable peripheral viral loads are still capable of transmitting 
drug-resistant HIV [172-174].  
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Chapter 2: Goal and objectives 
 
Goal 
The goal of this dissertation was to enhance the current understanding of the relationship between 
self-reported non-adherence to antiretroviral therapy and both factors related to non-adherence 
and clinical outcomes in HIV-infected individuals using state of the art methodology.   
Objectives 
1. To develop an understanding of the factors affecting self-reported non-adherence to cART 
incorporating correlates from the following 5 dimensions identified by the World Health 
Organization (WHO): a) social/economic, b) patient, c) condition, d) treatment, and e) 
system.   
2. To explore patterns and changes in self-reported adherence over time and to examine 
predictors of changes in adherence from five dimensions of the WHO. 
3. To assess the relationship between self-reported non-adherence and treatment failure as a 
form of validation of the Swiss HIV Cohort Study adherence questionnaire (SHCS-AQ).   
4. To assess the causal relationship between self-reported non-adherence and clinical 
outcomes using marginal structural models to adjust for confounding due to selection bias 
and lost to follow-up.   
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Chapter 3: Adherence measurement in the Swiss HIV Cohort Study 
1. The Swiss HIV Cohort Study 
The Swiss HIV Cohort Study (SHCS) is an ongoing multi-center, prospective observational research 
study initially funded by the Swiss Federal Office for Public Health and now financed by the Swiss 
National Science Foundation [1].  Seven centers began enrolling patients in 1988 and a total of 
15,694 individuals have been registered as of May 2009 (www.shcs.ch). The SHCS is estimated to 
include approximately 45% of the total number of HIV infections declared to Swiss health authorities 
and 69% of people with AIDS living in Switzerland [1]. The number of newly registered patients in the 
SHCS has changed in parallel to the character or trends in the epidemic of the disease in the Swiss 
population. As of 2008, 30.5% of actively followed patients were women and the main transmission 
groups were heterosexual (38.8%) and MSM (40.1%). 
Sociodemographic and behavioral data are collected at registration into the study. Official cohort 
visits occur every 6 months where laboratory and clinical data are collected.  Over time, increasing 
amounts of information have been added to the standard data collection including cardiovascular 
risk factors and sexual risk behavior (2000), alcohol consumption (2005), and in-depth information 
on IDU (2007). Data on adherence to ART was collected in a pilot phase beginning in January 2003 
with full data collection beginning in July 2003. 
2. Adherence questions 
Due to feasibility constraints the SHCS adherence questionnaire (SHCS-AQ) includes only 2 of the 4 
relevant dimensions of adherence behavior, taking adherence and drug holidays.  The following 
questions are recorded at each semi-annual cohort visit:  
1. How often was a dose of ART missed in the previous 4 weeks? 
a)       Never 
b) Once a month 
c)        Once every 2 weeks 
d) Once a week 
e)     More than once a week 
f)   Every day 
2. Did you miss more than one dose in a row in the last 4 weeks?   
a)       Yes 
b) No 
 44 
3. Definition of non-adherence 
Given these two questions, one must still define what qualifies as non-adherence.  As discussed in 
Chapter 1, previous research suggests that the implications of non-adherence vary by regimen class, 
with NNRTIs being more forgiving of missed doses with respect to viral failure but less forgiving with 
respect to drug resistance [2, 3]. However the exact level of adherence necessary by regimen class to 
achieve good clinical outcomes is not clear. Therefore, non-adherence was defined independent of 
regimen class with interactions between adherence and regimen class considered in models of 
clinical outcomes.  
Three definitions of non-adherence are used throughout the manuscripts depending on the study 
design and analysis method. The first and most conservative definition is to consider any missed 
dose of ART to be non-adherence.  The second definition of non-adherence is missing more than 1 
dose of ART. The third definition translates the answers of the first question into number of missed 
doses in the last 4 weeks: 0, 1, 2, and >2. These definitions allow us to examine the effects of 
different levels of non-adherence. 
4. Data collection and social desirability bias 
The SHCS-AQ is administered via interview with the attending physician or nurse. This method of 
data collection may lead to overreporting of adherence which could be minimized with a self-
administered questionnaire [4]. First, social desirability bias may lead an individual to intentionally 
over report their adherence to avoid discomfort. Second, misremembering of adherence is thought 
to be the main reason why self-report overestimates adherence as the repetitive routine of pill-
taking leads to poor memory for the event [5]. Misremembering might be minimized, however, if 
patients were given more time to consider their answers when completing the questionnaire 
themselves.  
Nested within the SHCS, a multi-center study exploring symptom experience and manageability, 
adherence, health-related quality of life, and disease progression in HIV-infected patients (SOLEXA) 
was conducted in 2006 [6, 7]. As part of this study, participants completed the SHCS-AQ via self-
administration. As an exploratory analysis into the extent of social desirability bias, questionnaires 
completed by the same patient via interview and self-administration were compared.  We included 
only those participants who completed both questionnaires within 30 days of each other for a 
sample of 182 (66.9%) out of the original 272 participating in SOLEXA.   
The responses were the same on both questionnaires 67.6% of the time; adherence estimates were 
higher during the interview than self-administration during 22.5% of the time and lower 9.9% of the 
time (Table 3.1).  We used Bowker’s test of symmetry to see if the paired responses between an 
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individual were statistically different.  The null hypothesis is that the probabilities in the square table 
satisfy symmetry (or that pij = pji) for all pairs of table cells. The null hypothesis was rejected with a p-
value of 0.03 indicating that the responses from the interview-administered questionnaire were 
significantly different from those given in the self-administered questionnaire. This provides some 
evidence of potential social desirability bias or over reporting of adherence during interviews with 
physicians. 
 
Table 3.1 Self-reported missed doses of antiretroviral therapy in the previous 4 weeks by mode of 
administration in participants of SHCS and SOLEXA (N=182) * 
 
 SHCS 
Interview-
administered 
n (%) 
SOLEXA  
Self-completion 
 
n (%) 
p-value√ 
  Missed doses # 
      0 
      1 
      2 
    >2 
 
138 (75.8) 
33 (18.1) 
5 (2.8) 
6 (3.3) 
 
116 (63.7) 
42 (23.1) 
10 (5.5) 
14 (7.7) 
 
0.03 
* SHCS = Swiss HIV Cohort Study; SOLEXA was a nested study within the SHCS  
#  Self-reported missed doses of antiretroviral therapy in the previous 4 weeks 
√ Bowker’s test of symmetry.  
 
Despite these arguments against this form of data collection, the reason for using interview to 
collect the data is two-fold.  Adherence is an important aspect of the clinical care of a patient and 
should be discussed openly and regularly with their treating physician.  Second, practical 
considerations of busy clinics make it difficult to implement other data collection methods. 
5. Validation of adherence questionnaire 
Deschamps and colleagues conducted a diagnostic study in 133 patients comparing three measures 
of self-reported adherence, the SHCS-AQ, European HIV treatment questionnaire, and a visual 
analogue scale (VAS), using both MEMS and virologic failure as reference standards [8]. Self-reported 
adherence was measured at baseline and again 3 months later. Adherence was monitored by MEMS 
for 3 months starting at baseline.  Viral load was measured every 3 months for 15 months starting at 
baseline. Virologic failure was defined as at least one viral load > 400 copies/ml or two consecutive 
viral loads >50 copies/ml.  
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When using MEMS as the reference standard, the combination of VAS and the SHCS-AQ performed 
better than the SHCS-AQ alone, however the diagnostic value was still low (sensitivity 66.7%, 
specificity 58.2%, area under the curve (AUC) 0.63). Using virologic failure at 1 year as the reference 
standard, the SHCS-AQ performed better than the other two self-report measures, SHCS-AQ 
combined with VAS, and MEMS with a sensitivity of 88%, specificity of 79%, and an AUC of 0.83. 
These results demonstrated that the SHCS-AQ is not only a simple and practical way to measure 
adherence in daily clinical practice but a valid one as well. 
This study also highlighted some of the problems discussed previously that can occur with the use of 
MEMS. Of the 133 eligible patients who agreed to participate in the study, 17 (12.8%) were not 
included due to inconsistent or incorrect use of the MEMS cap and 36% of participants admitted to 
using the MEMS cap inconsistently. Another 41% reported using pill boxes to organize their 
medications which could have led to incorrect measurements with MEMS. 
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Abstract 
 
Background 
Adherence is one of the most crucial issues in the clinical management of HIV-infected patients 
receiving antiretroviral therapy (ART).  
 
Methods 
A two-item adherence questionnaire was introduced into the Swiss HIV Cohort Study in July 2003. All 
3607 eligible patients were on ART for 6 months and their current regimen for 1 month. Three 
definitions of non-adherence were considered: missing 1 dose, missing 2 doses and taking <95% 
of doses in the last 4 weeks.   
 
Results 
Over 30% of patients reported missing 1 dose, 14.9% missed 2 doses, and 7.1% took <95% of 
doses in the previous 4 weeks. The rate of drug holidays was 5.8%. Whether using more or less 
conservative definitions of non-adherence younger age, living alone, number of previous regimens 
and boosted PI regimens were independent factors associated with non-adherence. There was a 
significant association between optimal viral suppression and non-adherence as well as a significant 
linear trend in optimal viral suppression by missed doses. 
 
Conclusions 
Younger age, lack of social support, and complexity of therapy are important factors that are related 
to non-adherence with ART. Investment in behavioral dimensions of HIV is crucial to improve 
adherence in ART recipients.  
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Introduction  
Antiretroviral therapy (ART) has lead to a substantial reduction in HIV associated morbidity and 
mortality and HIV infection has entered the stage of chronic disease management [1-4]. Lasting 
suppression of viral replication is the goal of ART and one of the most important factors influencing 
long-term prognosis of HIV-infected individuals [5,6]. Factors associated with the failure of viral 
suppression and progression to AIDS or death are low CD4 cell counts and viremia at the start of 
ART, non-naiveté to ART, adverse drug reactions and non-adherence to ART [7-11]. 
Non-adherence increases the risk of viral mutations, which can result in cross-resistance to other 
medications [12-14] or transmission of multi-resistant virus strains, and thus the risk for initial 
therapy failure in subsequently infected individuals [15,16]. Although preliminary evidence indicates 
that even high and sometimes complete adherence does not prevent accumulation of HIV drug 
resistance mutations, sub-optimal adherence remains a critical issue in the development of 
resistance [13,17]. Adherence is imperative to guarantee the effectiveness of ART [18-20]. 
The medication event monitoring system (MEMS) is the most reliable and sensitive method to assess 
adherence [18], but not feasible in a large HIV-infected population such as the Swiss HIV Cohort 
Study (SHCS) largely due to cost. Patient self report has the advantage of low cost, simplicity and 
feasibility, correlates reasonably well with viral load and suppression [21] but can overestimate 
adherence rates due to recall bias and social desirability [22]. 
The goals of this study were to determine the prevalence of self-reported adherence to ART in the 
SHCS and to explore relationships between socioeconomic-, patient-, condition-, therapy-, and 
system-related factors and self-reported adherence to ART. 
 
Methods 
Patients  
The SHCS is a prospective cohort study with continuing enrollment of HIV-infected individuals aged 
16 years or older. Beginning in July 2003, an adherence questionnaire was introduced into the 
cohort follow-up. Visits take place every 6 months at 7 outpatient clinics from participating HIV 
centers, associated hospitals, or specialized private practices. Eligible individuals were actively 
enrolled in the SHCS and on potent ART for at least 6 months and their current regimen for at least 1 
month at the time of their first cohort visit after July 2003.  Potent ART was defined as any 2-class 
regimen from a protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI), non-
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nucleoside reverse transcriptase inhibitor (NNRTI) or fusion inhibitor (FI) class, or a triple NRTI 
regimen. A treatment interruption of less than 4 weeks was allowed except in the 4 weeks 
immediately prior to the date the questionnaire was completed. 
Outcome definition 
There are four dimensions of adherence that merit consideration when focusing on the behavioral 
dimension of adherence to ART: taking adherence (the extent to which a patient is taking a 
prescribed drug regimen), timing adherence (the extent a patient is adhering to the prescribed 
schedule for the drug intake), drug holidays (the extent a patient is missing several doses in a row), 
and food restrictions (the extent a patient is adhering to drug intake in relation to food restrictions). 
Due to feasibility constraints, the SHCS adherence questionnaire contains only two questions: taking 
adherence (How often did you miss a dose in the last 4 weeks: daily, more than once a week, once a 
week, once every second week, once a month, never); and drug holidays (Did you have a period of 
no drug intake for > 24 hours in the last 4 weeks: yes, no). As there is no standard definition of non-
adherence, we considered three definitions, each increasingly less conservative: 1) missing one or 
more doses of medication, 2) missing two or more doses of medication, and 3) taking less than 95% 
of prescribed doses of ART in the last 4 weeks.  
Covariate definitions 
At each cohort visit, laboratory measurements are taken and information on cardiovascular risk 
factors and social support is collected.  In addition, any changes in treatment, such as dose, drugs, 
toxicity and reasons for switching drugs, are recorded.  Using the new taxonomy of the WHO [23], 
correlates of non-adherence can be categorized as 1) socioeconomic-related factors, 2) patient-
related factors, 3) condition-related factors, 4) treatment-related factors, and 5) system-related 
factors.  We considered the following socioeconomic-related factors: gender, age, ethnicity, 
education level (completed 9 years of mandatory schooling or less vs. higher), having a stable 
partner in the previous 6 months, and currently living alone.  Patient-related factors were current IV 
drug use or being in IV drug maintenance program and seeking psychiatric treatment in the last 6 
months. Condition-related factors included progression to AIDS, time on current ART, and time on 
ART. Treatment-related factors were number of previous ART regimens, daily pill burden, dose 
frequency (once daily, twice daily, three or more times a day), drug class of current regimen (NNRTI, 
boosted PI, non-boosted PI, triple nucleoside), ART toxicity since the year 2000, fat loss or fat gain in 
the last 12 months, and current use of co-medications (opportunistic infections, hepatitis C, risk 
factors of cardiovascular disease). The system-related factor was the center where the patient had 
their last visit.  
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Definitions of surrogate markers for HIV infection  
Optimal viral suppression was defined as having plasma HIV RNA (viral load) < 50 copies/ml allowing 
for non-consecutive blips (50  HIV RNA  400 copies/ml) over the previous 6 months.  Two 
consecutive blips or a viral load > 400 copies/ml was considered non-optimal viral suppression. Any 
increases in CD4 cell count of > 50 or >100 x 109/L in the previous 12 months was considered.  
Statistical methods 
For each of the three outcomes, univariate and multivariable logistic regression models were used to 
assess the association between the outcome and covariates. Initially, univariate models were fit and 
factors associated with non-adherence (P<0.10) were entered into multivariable models. Some 
factors were excluded from the multivariable model due to multicollinearity. To adjust for potential 
correlation in adherence behavior within patients at the same center, a multilevel mixed model was 
fit to the data with center as a random effect. Likelihood ratio tests were used to determine 
significant associations between covariates and non-adherence.  Odds ratios (OR) and 95% 
confidence intervals were estimated.  The association between surrogate markers of HIV infection 
and the outcomes was assessed in sensitivity analyses. Linear trends in the data were assessed using 
the Cochran-Armitage trend test. All analyses were done with Stata 8.0 and SAS version 8.2. 
 
Results 
Sample population and non-responders 
A total of 5861 individuals was registered in the SHCS and had not dropped out prior to July 1, 2003.  
Of these, 1458 were not on treatment and 128 did not complete an adherence questionnaire.  In 
addition, 668 did not meet the treatment criteria: 619 were not on potent ART for at least 6 months 
and 49 were not on their current regimen for at least 4 weeks.  A total of 3607 individuals were 
included in the analysis. 
The 668 patients who did not meet eligibility criteria were more likely to be female (33.7% vs. 
28.6%), have a basic education (30.9% vs. 25.7%), not be in a stable partnership (48.8% vs. 40.8%), 
use IV drugs (15.0% vs. 10.3%), and been HIV+ for a shorter period of time (8 vs. 10 years) compared 
to the analysis population.  
Self reported non-adherence 
Self-reported non-adherence over the previous 4 weeks was as follows: 31.1% of patients reported 
missing one or more doses (range across centers: 26.1%-41.5%); 14.9% reported missing 2 or more 
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doses (range across centers: 11.0%-22.3%); and 7.1% of patients took <95% of prescribed ART doses 
(range across centers: 4.3%-12.3%). Almost 6% reported taking a drug holiday (no drug intake in > 24 
hours) in the last 4 weeks (Table 4.1).  
 
Table 4.1 Self-reported non-adherence to potent ART in the SHCS 
Total no. of patients 3607 
How often a dose was missed in last 4 weeks  - % 
   Never 
   Once a month 
   Once every 2 weeks 
   Once a week 
   More than once a week 
   Every day 
 
68.9 
17.3 
6.7 
3.1 
3.1 
1.0 
Drug holidays - % 
    No drug intake > 24 hours 
 
5.8 
  
Percent adherence  in the last 4 weeks 
      95% 
     90-95% 
     < 90% 
 
92.9 
6.0 
1.1 
Non-adherence in the last 4 weeks 
     Missed  1 dose  
     Missed  2 doses  
 
31.1 
14.9 
 
 
Adherence rates by potential correlates (Table 4.2a) and surrogate markers of HIV infection (Table 
4.2b) are provided. The more non-adherent individuals become the worse the HIV infection profile. 
Over 78% of all patients were optimally virally suppressed during the previous 6 months, this 
percentage dropped to 72.1% in those who missed 1 dose of medication, 64.0% in those who 
missed  2 doses and to 58.4% in those with <95% adherence. The percentage of individuals with 
increases in CD4 count of >50 cell per 109/l in the previous year decreased from 57.1% to 49.8% with 
diminishing adherence. Of those who reported taking a drug holiday, only 52.8% were optimally 
virally suppressed compared to 80.4% of those who did not report taking a drug holiday. A strong 
linear relationship was found between the number of missed doses and optimal viral suppression 
(Figure 4.1) and the test for linear trend was highly significant (p<0.0001).  
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Table 4.2a Adherence rates by potential correlates and surrogate markers of HIV infection 
 All patients Missed 1 dose  Missed 2 doses  <95% doses  
Total – n (%) 3607 (100) 1123 (31.1) 537 (14.9) 258 (7.2) 
Age in years – Mean (SD)  43.5 (9.7) 42.5 (9.1) 42.2 (9.0) 41.4 (8.3) 
Male Gender – % 71.4 68.6 67.2 65.5 
Race – % 
    Caucasian 
    Black 
    Hispano-American 
    Asian 
    Other/Unknown 
 
82.7 
9.6 
1.8 
3.2 
2.6 
 
81.0 
10.3 
2.1 
2.9 
3.6 
 
79.0 
11.0 
2.4 
3.9 
3.7 
 
75.2 
13.2 
2.7 
4.7 
4.3 
Basic Education – % 25.7 29.2 31.3 37.7 
Stable Partnership – % 59.2 59.3 56.8 56.0 
Living Alone – % 41.5 44.6 45.4 48.0 
Current IDU or drug program § – % 10.3 13.1 13.8 18.3 
Psychiatric treatment § - % 7.1 8.6 8.6 8.9 
AIDS - % 30.1 28.9 29.8 31.4 
Years on current ART - Mean (SD) 
Years on all previous ART – Mean (SD) 
2.2 (1.7) 
4.6 (2.8) 
2.3 (1.7) 
4.6 (2.8) 
2.2 (1.8) 
4.5 (2.9) 
2.1 (1.6) 
4.1 (2.8) 
Years since 1
st
 pos HIV test – Mean (SD) 10.1 (5.5) 11.1 (5.3) 11.2 (5.2) 11.0 (5.2) 
No. of previous regimens – Mean (SD)  4.3 (3.3) 4.6 (3.4) 4.9 (3.6) 4.9 (3.6) 
Daily pill burden - % 
   Mean (SD)  
    < 7  
    7 – 11  
     12  
 
7.6 (5.1) 
50.1 
22.7 
27.3 
 
8.0 (5.3) 
46.7 
24.3 
29.0 
 
8.3 (5.2) 
42.6 
27.1 
30.3 
 
8.1 (5.5) 
44.4 
25.7 
30.0 
ART Toxicity ‡ - %  
    Major toxicity 
    Other toxicity 
    None 
 
26.1 
19.2 
54.8 
 
26.1 
19.8 
54.1 
 
27.2 
23.3 
49.5 
 
28.7 
24.8 
46.5 
Lipodystrophy - %  
    Any fat loss 
    Any fat gain 
 
30.6 
28.9 
 
29.8 
28.5 
 
28.0 
28.6 
 
25.2 
28.0 
Dose frequency - %  
    Once daily 
    Twice daily 
    Three time or more daily 
 
5.2 
91.8 
3.1 
 
3.8 
92.7 
3.5 
 
3.4 
92.7 
3.9 
 
5.8 
93.0 
1.2 
Current drug regimen - % 
    NNRTI 
    PI – boosted 
    PI – non-boosted 
    Triple nucleoside 
 
32.2 
25.9 
25.0 
16.9 
 
27.8 
26.7 
27.3 
18.3 
 
24.8 
27.8 
29.8 
17.7 
 
21.7 
24.0 
31.8 
22.5 
Current co-medication - % 
    Cardiovascular risk factors 
    Hepatitis C 
    Opportunistic Infections 
 
2.6 
0.9 
4.1 
 
2.9 
0.6 
2.9 
 
2.8 
0.6 
3.5 
 
2.3 
0.8 
5.0 
*   Non-adherence in the previous 4 weeks  
§   In the 6 month period prior to the adherence questionnaire. 
‡  Any ART toxicity since the year 2000.  Major toxicities were abnormal fat distribution, hypersensitivity 
reaction, abdominal/GI tract, nervous system, and hematologic toxicity. 
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Table 4.2B Adherence rates by potential correlates and surrogate markers of HIV infection 
 All patients Missed 1 
dose  
Missed 2 
doses  
<95% doses 
taken 
Total – n (%) 3607 (100) 1123 (31.1) 537 (14.9) 258 (7.2) 
Optimal Viral Suppression † 78.9 72.1 64.0 59.2 
HIV RNA viral load (copies/ml) - % ‡ 
   Mean (SD) of log copies/ml 
   < 50  
   50-399 
    400  
 
1.8 (3.0) 
79.5 
9.0 
11.5 
 
2.4 (3.4) 
72.5 
9.7 
17.8 
 
3.1 (3.8) 
64.2 
10.7 
25.1 
 
3.7 (4.1) 
58.4 
11.0 
30.6 
CD4 increase (cells per 10
9
/l) - % § 
    > 50  
    > 100 
 
57.1 
34.4 
 
54.7 
33.5 
 
50.9 
31.9 
 
49.8 
33.0 
CD4 count (cells per 10
9
/l ) - %  ‡ 
    Mean (SD) 
    < 200 
    200 – 349 
    350 – 499 
     500 
 
492.6 (279) 
11.0 
22.8 
24.7 
41.6 
 
488.5 (268) 
10.8 
21.7 
26.9 
40.7 
 
463.4 (268) 
12.9 
23.9 
26.5 
36.7 
 
452.6 (263) 
14.6 
23.7 
26.1 
35.6 
*   Non-adherence in the previous 4 weeks 
†   In the 6 month period prior to the adherence questionnaire. For definition see Methods section. 
‡   Closest to the date of the adherence questionnaire  
§   In the 12 month period prior to the adherence questionnaire. 
 
Univariable results 
Across all three definitions of adherence, univariate models showed that individuals of younger age, 
female gender, basic education, living alone, currently using IV drugs, with higher number of 
previous ART regimens, higher daily pill burden, and not on an NNRTI-based regimen were more 
likely to non-adhere to therapy (Table 4.3). Pill burden was not included in the multivariable models 
due to high correlation with drug regimen.  
Multivariable results 
Table 4.3 provides the results of the multivariable models. For all three definitions of adherence, 
individuals of younger age, living alone, higher number of previous ART regimens, and those on a 
boosted PI regimen were significantly more likely to non-adhere to therapy in the previous 4 weeks. 
Odds ratios and confidence intervals were similar for all models although the effect strengthened as 
the definition of adherence became less conservative. In all models, there was a significant amount 
of variation in non-adherence explained by the center where the patient had their follow-up visit 
even after adjusting for all other variables in the model. 
In each of the three final models, additional variables were significantly associated with non-
adherence in the multivariable model. For non-adherence defined as missing 1 dose, individuals on 
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their current regimen for a longer time (OR 1.08, 95%CI: 1.02 – 1.13) were more likely to non-adhere 
to therapy, whereas individuals taking co-medication for opportunistic infections (OR 0.65, 95% CI: 
0.43-0.98) were less likely to non-adhere to therapy. For non-adherence defined as missing 2 
doses, individuals on a non-boosted PI regimen (OR 1.53, 95% CI: 1.15-2.04) were more likely to non-
adhere to therapy, whereas individuals with reported fat loss (OR 0.76, 95% CI: 0.60-0.95) were less 
likely to non-adhere to therapy. For non-adherence defined as taking <95% of doses, individuals with 
a basic education (OR 1.42, 95% CI: 1.04-1.94), current IV drug users (OR 1.67, 95% CI: 1.12-2.51), 
and on a non-boosted PI regimen (OR 1.70, 95% CI: 1.12-2.57) or a triple nucleoside regimen (OR 
2.03, 95% CI: 1.33-3.11) were more likely to non-adhere to therapy, whereas individuals of Caucasian 
race (OR 0.66, 95% CI: 0.46-0.95), and with reported fat loss (OR 0.63, 95% CI: 0.45-0.88) were less 
likely to non-adhere to therapy. 
 
Figure 4.1 Proportion virally suppressed in previous 6 months 
  
 
Sensitivity analyses  
As a sensitivity analysis, surrogates of HIV infection (optimal viral suppression and increases in CD4 
count of >50 cells) were added to the final multivariable models.  Individuals who were optimally 
virally suppressed over the previous 6 months were significantly less likely to non-adhere (p<0.001) 
in all three multivariable models (1 dose: OR 0.62, 95% CI 0.51-0.75; 2 doses: OR 0.49, 95% CI 
0.39-0.62; <95% adherence: OR 0.44, 95% CI 0.32-0.60).  Individuals with increases in CD4 cell count 
of >50 cells x 10/l were significantly less likely to non-adhere only as the definition of non-adherence 
  
             Table 4.3 Correlates of self-reported non-adherence to potent antiretroviral therapy (ART) in the last 4 weeks 
Factor dimensions Missed  1 dose Missed  2 doses <95% of drugs taken 
 Univariate  
OR (95% CI) 
Multivariable 
OR (95% CI) 
p-value Univariate  
OR (95% CI) 
Multivariable 
OR (95% CI) 
p-value Univariate  
OR (95% CI) 
Multivariable 
OR (95% CI) 
p-value 
Socioeconomic-related           
    Age (in years)  0.98 (0.98-0.99) 0.98 (0.97-0.99) <0.001 0.98 (0.97-0.99) 0.98 (0.97-0.99) 0.002 0.97 (0.96-0.99) 0.98 (0.96-1.00) 0.02 
    Male Gender  0.83 (0.71-0.97) 0.88 (0.74-1.05) 0.16 0.81 (0.67-0.99) 0.90 (0.72-1.13) 0.36 0.78 (0.59-1.02) 0.98 (0.72-1.35) 0.92 
    Caucasian race  0.88 (0.73-1.07)   0.79 (0.63-0.99) 0.88 (0.67-1.16) 0.37 0.67 (0.49-0.90) 0.66 (0.46-0.95) 0.03 
    Basic Education  1.25 (1.06-1.49) 1.11 (0.93-1.33) 0.23 1.37 (1.11-1.69) 1.15 (0.91-1.45) 0.23 1.76 (1.33-2.32) 1.42 (1.04-1.94) 0.03 
    Stable Partnership  1.01 (0.87-1.17)   0.89 (0.74-1.08)   0.87 (0.67-1.13)   
    Living Alone  1.19(1.03-1.37) 1.26 (1.08-1.47) 0.003 1.18 (0.98-1.42) 1.27 (1.04-1.56) 0.02 1.30 (1.00-1.68) 1.55 (1.17-2.05) 0.002 
Patient & Condition-related           
   Current IDU or drug program 1.47 (1.18-1.84) 1.18 (0.92-1.52) 0.19 1.50 (1.14-1.98) 1.22 (0.89-1.68) 0.22 2.05 (1.46-2.88) 1.67 (1.12-2.51) 0.01 
    Psychiatric treatment 1.42 (1.09-1.85) 1.26 (0.92-1.52) 0.12 1.32 (0.95-1.85) 1.14 (0.78-1.65) 0.50 1.37 (0.87-2.15)   
    AIDS  0.92 (0.78-1.07)   1.00 (0.81-1.22)   1.09 (0.83-1.43)   
    Time on current ART (years)  1.06 (1.02-1.11) 1.08 (1.02-1.13) 0.004 1.03 (0.97-1.08)   1.00 (1.00-1.00)   
    Time on ART (years)  1.00 (0.98-1.03)   0.99 (0.95-1.02)   0.94 (0.89-0.98) 0.96 (0.91-1.01) 0.12 
Treatment-related           
    No. of previous regimens   1.04 (1.01-1.06) 1.05 (1.02-1.07) <0.001 1.05 (1.02-1.08) 1.06 (1.03-1.10) <0.001 1.04 (1.00-1.07) 1.08 (1.03-1.12) 0.001 
    Daily pill burden  
           < 7  
           7 – 11  
            12 
 
1.0 
1.31 (1.09-1.57) 
1.34 (1.13-1.59) 
   
1.0 
1.76 (1.39-2.22) 
1.72 (1.37-2.16) 
   
1.0 
1.52 (1.10-2.10) 
1.64 (1.20-2.24) 
  
    ART Toxicity †  
        Other toxicity 
        None 
 
0.99 (0.83-1.17) 
1.02 (0.82-1.26) 
   
0.88 (0.71-1.10) 
1.19 (0.92-1.56) 
   
0.79 (0.58-1.08) 
1.18 (0.83-1.68) 
  
    Lipodystrophy in previous year 
       Any fat loss  
       Any fat gain 
 
0.91 (0.78-1.06) 
0.92 (0.78-1.07) 
   
0.82 (0.67-1.01) 
0.93 (0.75-1.15) 
 
0.76 (0.60-0.95) 
 
0.02 
 
0.70 (0.52-0.94) 
0.89 (0.66-1.18) 
 
0.63 (0.45-0.88) 
 
0.008 
    Dose frequency  
        Once daily 
        Twice daily 
        Three times or more daily 
 
0.62 (0.43-0.88) 
1.0 
1.26 (0.85-1.89) 
 
0.69 (0.46-1.03) 
1.0 
1.16 (0.75 -1.78) 
 
0.07 
- 
0.51 
 
0.58 (0.35-0.95) 
1.0 
1.52 (0.93–2.49) 
 
0.56 (0.31-1.01) 
1.0 
1.31 (0.77 –2.22) 
 
0.06 
- 
0.31 
 
1.06 (0.61-1.83) 
1.0 
0.41 (0.13-1.31) 
  
    Current drug regimen  
        NNRTI 
        PI – non-boosted 
        PI – boosted 
        Triple nucleoside 
 
1.0 
1.48 (1.21-1.81) 
1.52 (1.25-1.86) 
1.31 (1.05-1.62) 
 
1.0 
1.19 (0.95-1.48) 
1.37 (1.10-1.69) 
1.19 (0.95-1.50) 
 
- 
0.13 
0.004 
0.13 
 
1.0 
1.80 (1.39-2.34) 
1.89 (146-2.44) 
1.31 (0.98-1.75) 
 
1.0 
1.53 (1.15-2.04) 
1.53 (1.15-2.03) 
1.24 (0.91-1.69) 
 
- 
0.004 
0.003 
0.18 
 
1.0 
1.76 (1.20-2.59) 
2.23 (1.56-3.19) 
1.95 (1.32-2.87) 
 
1.0 
1.70 (1.12-2.57) 
1.98 (1.32-2.92) 
2.03 (1.33-3.11) 
 
 
0.01 
0.001 
0.001 
    Co-medication  
        Cardiovascular 
        Hepatitis C 
        Opportunistic Infections 
 
1.16 (0.74-1.80) 
0.65 (0.28-1.53) 
0.61 (0.41-0.91) 
 
 
 
0.65 (0.43-0.98) 
 
 
 
0.04 
 
1.11 (0.63-1.96) 
0.68 (0.20-2.26) 
0.89 (0.54-1.46) 
   
0.92 (0.40-2.14) 
1.05 (0.25-4.47) 
1.37 (0.76-2.47) 
  
†  Any ART toxicity since the year 2000.  Reference group was major toxicities defined as abnormal fat distribution, hypersensitivity reaction, abdominal/GI tract, nervous system, and 
hematologic. 
  
became less conservative (2 missed doses: OR 0.73, 95% CI 0.59-0.91, p=0.004; <95% adherence: 
OR 0.69, 95% CI 0.51-0.93, p=0.02).  
With all three adherence outcomes, most odds ratios for original covariates remained very similar 
with slightly wider confidence intervals but with no resulting change in significance. Exceptions were 
that once daily became significant (OR 0.48, 95% CI 0.25-0.92) for missing 2 doses, and age, basic 
education, and non-boosted PI regimen became non-significant (p>0.05) for <95% adherence. 
 
Discussion 
To our knowledge, this is the largest study so far to look at correlates of self-reported non-
adherence in HIV-infected individuals. The analysis population includes individuals receiving ART for 
at least 6 months and has large proportions of women and patients from different ages and HIV 
transmission groups.  
A clinically meaningful definition of the level of adherence below which patients with HIV are at risk 
for poor virologic outcome has yet to be determined. For this reason, we chose relatively 
conservative definitions of non-adherence because even minimal deviations in dosing are known to 
affect outcome [18] and self-report is associated with underreporting of non-adherence [23,24]. 
With the most conservative definition of non-adherence we found 31.1% of patients missing 1 
doses of ART, which is lower than non-adherence rates between 40% and 80% that have been found 
by others both in clinical trials and clinical practice settings. These differences may in part depend on 
operational definitions, case finding or measurement methods for non-adherence [23]. 
We were unable to detect a significant association between non-adherence and gender and the 
significance of ethnicity and education depended on the definition of non-adherence, which could 
explain the conflicting results found in previous studies [18,19,25,26]. We included an indicator of 
those seeking psychiatric treatment in the previous 6 months, as this may capture those who suffer 
from anxiety or depression, known correlates of non-adherence [18,27,28]. However, we did not 
have sufficient power to detect an association. We did not detect an association between non-
adherence and reported ART toxicity, which was defined as the reason an individual stopped a 
particular drug since the year 2000. This definition might not accurately measure symptom distress 
due to side effects, which was found to significantly correlate with non-adherence [29,30]. 
Utilizing more liberal definitions of non-adherence strengthened several trends found with the most 
conservative definition with respect to race, education, IV drug use, triple nucleoside therapy, and 
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fat loss. Individuals on a non-boosted PI regimen were just as likely to miss 1 dose, but were more 
likely to miss 2 doses or to take < 95% of ART doses when compared to those on an NNRTI-based 
regimen. This could be due to the higher pill burden and dosing frequency for PI-based regimens.    
It is increasingly recognized that system factors are an understudied but important set of 
determinants of compliance [31]. This study found that for definitions of non-adherence, compliance 
rates differed between centers even after controlling for a range of other factors. This is an 
important finding as these center differences might be a proxy of differences in clinical and 
behavioral management of patients among centers, such as continuous compliance assessment, 
support provided in patient's self management, and quality of relationship between patient and 
health care provider.  
In a sensitivity analysis, we found a statistically significant association between non-adherence and 
optimal viral suppression that strengthened, as the definition of non-adherence became less 
conservative. Our results add to evidence from previous studies that have demonstrated acceptable 
correlation between self-reported drug adherence and HIV-1 plasma viral load [12,17,21,32-34], thus 
providing clinical validation of self-reported drug intake in HIV-infected individuals taking ART. 
Previously, conflicting results were found between CD4 cell counts and non-adherence [19,30]. In 
this analysis, we found a significant association between non-adherence and increases in CD4 cell 
count only with the two least conservative definitions of non-adherence. 
This study has several strengths. We defined adherence in three different ways using two simple 
questions that are easy to understand and clinically relevant. We have detailed data on treatment 
from a large cohort of HIV-infected individuals and our analysis had the power to verify suspected 
trends in adherence. In addition, detailed treatment information is collected on individuals in the 
SHCS allowing us to explore a large range of treatment-related variables. We controlled for 
variations in non-adherence across centers providing a more accurate picture of real trends in the 
data.  
This study also has several limitations. The analysis is based on cross-sectional, not prospective, data 
and therefore no causal conclusions can be drawn. In addition, we did not have information on food 
restrictions or alcohol abuse, variables known to be correlated with non-adherence [18,27,28]. 
Adherence has become one of the most crucial issues in the clinical management of HIV-infected 
patients receiving ART to achieve sustained long-term suppression of HIV replication and to avoid 
resistance to antiretroviral drugs. These results confirm the importance of understanding the 
necessary level of non-adherence as it relates to patient outcomes. Health care providers need to 
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provide the foundation and support for the behavioral dimension of long-term disease management 
and recognize that younger patients and those without social support are at increased risk for non-
adherence. Preliminary evidence from our study suggests that patients on NNRTI regimens, 
especially when compared to those on PI regimens, may be at lower risk for non-adherence. 
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Abstract 
Background 
Adherence to antiretroviral therapy (cART) is a dynamic process however changes in adherence 
behavior over time are insufficiently understood.  
Methods 
Data on self-reported missed doses of cART was collected every 6 months in Swiss HIV Cohort Study 
participants. We identified behavioural groups associated with specific cART adherence patterns 
using trajectory analyses. Repeated measures logistic regression identified predictors of changes in 
adherence between consecutive visits.   
Results 
6709 individuals completed 49,071 adherence questionnaires (median 8 (interquartile range (IQR): 5 
– 10) during a median follow-up time of 4.5 years (IQR: 2.4 – 5.1).  Individuals were clustered into 4 
adherence groups: good (51.8%), worsening (17.4%), improving (17.6%), and poor adherence 
(13.2%). Independent predictors of worsening adherence were younger age, basic education, loss of 
a roommate, starting intravenous drug use, increasing alcohol intake, depression, longer time with 
HIV, onset of lipodystrophy, and changing care provider. Independent predictors of improvements in 
adherence were regimen simplification, changing class of cART, less time on cART, and starting co-
medications.  
Conclusion 
Treatment, behavioural changes and life events influence patterns of drug intake in HIV patients. 
Clinical care providers should routinely monitor factors related to worsening adherence and 
intervene early to reduce the risk of treatment failure and drug resistance. 
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Introduction 
Combination antiretroviral therapy (cART) has lead to dramatic reduction in hospitalization rates, 
opportunistic infections, and deaths associated with HIV infection [1-4].  Continuous and lasting 
suppression of viral replication is essential to allow for maximal CD4 cell recovery, the most 
important factors influencing long-term prognosis of HIV-infected individuals [5,6]. Adherence to 
cART is paramount to achieving these goals and non-adherence to therapy has been shown to be 
one of the strongest predictors of virological failure [7,8].  In addition, non-adherence has been 
linked to the emergence of drug resistance, often associated with cross-resistance to other members 
of the same class, limiting future treatment options and possible transmission of multidrug resistant 
virus [9-11].  
Factors associated with adherence have been well documented [12-15].  Findings from our previous 
research have shown that younger age, lack of social support, increasing number of previous 
regimens, taking a protease inhibitor (PI), regimen complexity, and taking medication for 
opportunistic infections were significantly associated with non-adherence [12].  However, adherence 
is a dynamic process and only a few studies have addressed patterns and changes in adherence over 
time [16-20]. Most of these studies only considered special populations, such as men having sex with 
men (MSM) [16,18] or women [16]. In addition, all studies had methodological limitations, such as 
dichotomizing or summarizing adherence data leading to inefficient use of data [16,18,19] and short 
follow-up [17-20].  
In order to optimally design adherence intervention studies, there is a need for a detailed and 
sophisticated analysis of adherence patterns. The Swiss HIV Cohort Study (SHCS) provides a unique 
opportunity to achieve this with 6 years of follow-up in a large prospective cohort where women, 
heterosexuals and intravenous drug users (IDU) are well-represented.  The goals of this study were 
to identify clusters of individuals with unique patterns of adherence behaviour and to assess factors, 
especially changes in factors, associated with changes in adherence over time.  
 
Methods 
Design 
This longitudinal study was based on prospectively collected data from individuals enrolled in the 
SHCS and followed at one of the 7 outpatient clinics (Basel, Berne, Geneva, Lausanne, Lugano, St. 
Gallen, Zurich) or associated clinics and private urban practices (www.shcs.ch).  At these routinely 
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scheduled visits, patients’ self-reported drug adherence and additional psychosocial, clinical and lab 
data are collected. Eligible individuals were either treatment experienced or starting cART and 
responded to at least two adherence questionnaires between its introduction on January 1, 2003 
and the end of study on January 1, 2009. Baseline was the date of the first completed adherence 
questionnaire. 
Measure of adherence  
The simplified SHCS adherence questionnaire contains two questions addressing taking adherence 
and drug holidays, 2 of the 4 dimensions of adherence to cART [21]. Taking adherence is defined as 
the number of missed doses in the last 4 weeks (daily, more than once a week, once a week, once 
every second week, once a month, never). Drug holidays are defined as missing two or more 
consecutive doses in the last 4 weeks (dummy variable).  
Definition of changes in adherence behaviour  
For the definition of change in adherence behaviour we formed consecutive visit pairs which 
constitute the unit of analysis. For each consecutive visit pair, changes in adherence from one visit 
(Vi) to the next (Vi + 1) is the outcome. We defined three possible groups: 1) individuals with no 
reported change in missed doses between two visits, 2) individuals who reported a change for the 
worse with more missed doses since the last visit and 3) individuals who reported improvements in 
adherence with less missed doses than the previous visit.  
Predictors of changes in adherence behaviour  
To model behaviour change in drug adherence we included predictors from five dimensions 
identified by the World Health Organization as affecting adherence to cART [21]: sociodemographic-, 
patient-, health condition-, treatment-, and health system-related factors. For time-updated 
predictors, changes in a predictor from one visit (Vi) to the next (Vi + 1) is modelled unless otherwise 
specified. The sociodemographic factors were age at baseline, gender, ethnicity (Caucasian vs. 
others), education (basic education vs. higher education), changes in stable partnership (loss of 
partner, gain of partner, no change) and living conditions (loss of roommate, gain of roommate, no 
change). Patient-related factors were collected via self-report at every follow-up visit and defined as 
follows. Changes in cigarette smoking (started smoking, quit smoking, no change), intravenous drug 
use (IDU) (started IDU, stopped IDU, no change), participation in drug substitution program (started 
drug program, stopped drug program, no change), and legal problems (developed legal problems, 
resolved legal problems, no change). Risky sex behaviour was defined as unprotected sex (without 
condoms) with either an HIV-negative stable partners or occasional partners. Changes in sexual risk 
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behaviour were included (riskier behaviour, less risky behaviour, no change).  Daily alcohol intake 
was translated into health risk categories developed by the WHO [22]: light (<20 g for women and 
<40 g for men), moderate (20-40 g for women and 40-60 g for men) and severe health risk (>40 g for 
women and >60 g for men) as done in a recent study [23]. Changes in categorization of alcohol risk 
were categorized as increased risk, decreased risk, or no change. Psychiatric treatment was defined 
as seeing a psychiatrist, diagnosis of depression or taking antidepressants. Although most patients 
seeking psychiatric treatment were likely suffering from depression, specific information on 
depression was only collected as of July 2008. Changes in psychiatric treatment were classified as 
started treatment, stopped treatment, or no change. Health condition-related factors, collected via 
patient interview and hospital records, were hospitalization since the previous visit, co-medication 
for opportunistic infections (OI), cardiovascular disease (CVD) prevention/treatment, hepatitis C or 
cancer (started co-medication, stopped co-medication, no change), and time since first HIV-1 
positive test at baseline (in years). Treatment-related factors were number of previous cART 
regimens at baseline, time on cART at baseline, changes in dosing frequency (increase in frequency, 
decrease in frequency, no change), and changes in class of cART since the previous visit (Yes, No). 
Class of cART is defined as non-nucleoside reverse transcriptase inhibitor (NNRTI), boosted PI, non-
boosted PI, or triple nucleoside/other.  Boosted PI regimens were defined as ritonavir with at least 
one other PI.  Body fat changes, defined as peripheral lipoatrophy or central or nuchal body fat gain 
as diagnosed by the clinician and confirmed by the patient, were included (new report of body fat 
changes, resolution of body fat changes, no change). Health system-related factors were changes in 
the physician or center where the individual was being followed since the previous visit.  
Statistical analysis  
Identification of patterns in adherence behaviour  
Due to the infinite number of possible individual-specific adherence patterns, we used group-based 
trajectory modeling for the identification of clusters of individuals with similar observed temporal 
patterns of adherence to cART [24]. Similar to latent class analysis [25], this method assumes that 
the population is composed of a mixture of distinct groups defined by their behavioral trajectories. 
This procedure allows joint modeling of the probability of group membership and group-specific 
trajectories. The latter are modeled semi parametrically via flexible polynomial functions fitted to 
individual adherence responses over time. Given a specified number of groups, the model estimates 
membership probabilities in each group for every participant, based on the participant’s observed 
patterns of adherence over time. Estimated variability in parameter estimates accounts for 
uncertainty in group membership and between-individual and within-individual variation in 
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observed longitudinal responses. The modeling was performed for 2 up until 6 groups with final 
selection of the optimal number of groups based on comparison of model fits using the Bayesian 
information criterion. Group assignments were based on posterior model-based probability 
calculations, with actual assignment based on the maximal group membership probability for each 
participant. Model results were summarized graphically with each groups predicted trajectories and 
their 95% confidence intervals. Baseline characteristics by group membership were summarized. 
Changes in adherence behavior 
To model changes in adherence behaviour, we constructed two datasets, one for improvements in 
and one for worsening of adherence.  All visit pairs with no reported changes in adherence (where 
the adherence on the initial visit pair was not perfect) and those with reported improvements in 
adherence at visit Vi+1 were included in the model exploring the likelihood of an improvement in 
adherence since the previous visit. All visit pairs with no reported changes in adherence (where the 
adherence on the initial visit pair was not in the lowest possible category) and those with reported 
decreases in adherence at visit Vi+1 were included in the model exploring the likelihood of a decrease 
in adherence since the previous visit. Both models included all pre-selected predictors from the 5 
WHO dimensions.  For time-independent factors (age, gender, ethnicity, education, time since HIV-1 
positive test, number of previous cART regimens), the value of the predictor at visit Vi was included 
in the model. For time-dependent factors, their change from one visit (Vi) to the next (Vi + 1) was 
modelled. We used generalized estimating equations to evaluate the repeated measures logistic 
regression models. This model adjusted for the correlation between visit pairs in the same individual. 
Results are presented with odds ratios and 95% confidence intervals.  
Sensitivity analyses  
To check the consistency of our results we performed several sensitivity analyses. For the description 
of adherence behaviour clusters, we repeated the trajectory analysis, stratifying the population by 
cART treatment – naïve or pre-treated. For the identification of adherence patterns, we performed 
three sensitivity analyses. First, we stratified the analysis by gender to check if different factors 
affect changes in adherence for men and women.  Second, we repeated the primary analysis 
stratifying by number of missed doses on the initial visit pair (Vi) to see if different factors influenced 
the likelihood of adherence changes depending on the initial adherence. Third, we removed changes 
in alcohol risk category from the multivariable model as this variable was only collected in the SHCS 
as of August 2005. Therefore, multivariable models including alcohol lose a lot of information which 
might impact the results even though these values were missing by design (completely at random).  
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All analyses were done with SAS version v9.1 (SAS Institute Inc., Cary, NC, USA) and Stata version v9 
(StataCorp. College Station, TX, USA). 
 
Results 
A total of 7466 individuals completed 69,144 adherence questionnaires between January 1, 2003 
and January 1, 2009. Of these, 19,238 were not completed during an official follow-up visit and 105 
were completed when an individual was not on cART; 654 individuals completed only one adherence 
questionnaire. The final analyses included 6709 individuals who completed 49,071 questionnaires 
and had 42,362 visit pairs during the 6 year study period. The median number of adherence 
questionnaires per individual was 8 (interquartile range (IQR): 5 – 10) and the median follow-up time 
was 4.5 years (IQR: 2.4 – 5.1) The population consisted largely of males (69.6%), Caucasians (82.1%), 
those with suppressed HIV-1 RNA at baseline (64.8% with <50 copies/ml), 38.4% were heterosexuals, 
median age was 41 years and individuals were diagnosed with HIV a median of 7.9 years ago (IQR: 
3.0 – 13.5)(Table 5.1). 
Missing 0 doses of cART was reported by patients on 78.1% of visits, missing 1 dose 13.1%, missing 2 
doses 4.7%, and missing >2 doses 4.2% of visits. Missing more than one dose in a row was reported 
on 3.5% of visits. Overall, self-reported adherence was found to be improving over time, with 70% 
reporting missing 0 doses of cART at the beginning of the 6-year study period compared to 83% at 
the end (Figure 5.1). In the subset of naïve patients, this trend remained but reports of missing 0 
doses increased from 81% to 87% over time (data not shown). 
Trajectory analysis was used to identify group patterns of adherence to cART. We considered groups 
of size 2 to 6 and selected a model of 4 groups as optimal based on fit (comparing the Bayesian 
Information Criterion between models), parsimony (comparing clusters in both naive and pre-
treated individuals) and interpretability. Group 1 (labelled “good adherence”) was estimated at 
51.8% and characterized by consistently high adherence (Figure 5.2).  Group 2 (labelled “worsening 
adherence”) was estimated at 17.4% and included individuals with good adherence at baseline 
followed by steadily worsening adherence. Group 3 (labelled “improving adherence”) was the 
opposite of Group 2 characterized by reports of poor adherence at baseline followed by steadily 
improving adherence and had an estimated group membership of 17.6%. Group 4 (labelled “poor 
adherence”) was estimated at 13.2% and characterized by consistent reports of poor adherence over 
time. There was very little overlap in the confidence intervals of the groups indicating the 
trajectories are relatively distinct. The same four adherence patterns were identified in separate  
 72 
Table 5.1 Baseline characteristics of population by membership in adherence pattern group 
identified by trajectory analysis 
Variable Overall 
 
Group 1: 
Good 
adherence
 
Group 2: 
Worsening  
adherence 
Group 3: 
Improving  
adherence 
Group 4: 
Poor  
adherence 
N (%) 6709 3837 (57.2) 927 (13.8) 1118 (16.7) 827 (12.3) 
Age – median (IQR) 41 (36-47) 42 (36-49) 41 (35-46) 41 (36-46) 40 (36-45) 
Male gender - % 69.6 71.3 66.7 68.4 65.7 
Caucasian - %  82.1 82.5 81.9 81.3 81.4 
Basic education # - % 26.7 23.3 29.4 30.9 34.1 
Risk group for HIV 
infection  
    MSM 
    Heterosexual 
    IDU 
    Other 
 
37.5 
38.4 
19.9 
4.2 
 
41.8 
38.9 
14.6 
4.7 
 
32.9 
39.7 
23.7 
3.7 
 
33.7 
38.6 
24.7 
3.0 
 
27.6 
34.6 
33.9 
4.0 
Past or current IDU 22.3 16.6 27.1 27.3 36.6 
Past or current psychiatric   
     treatment  
22.8 19.4 24.4 27.4 30.2 
Past or current legal  
     problems  
9.9 6.9 13.2 11.6 17.7 
Living alone 41.1 40.3 39.3 42.6 45.0 
Stable partnership 57.3 58.9 55.5 54.9 54.9 
Baseline viral load  
   (copies/ml) - % 
    < 50 
    50 – 399 
    ≥ 400 
 
64.8 
15.4 
19.8 
 
66.1 
15.9 
18.0 
 
64.7 
14.9 
20.4 
 
63.1 
15.5 
21.5 
 
61.3 
13.7 
25.0 
Baseline CD4 cell count  
   (μ/L) - % 
     < 200 
     200 – 349  
     350 – 499  
     ≥ 500 
 
16.4 
26.8 
24.2 
32.6 
 
16.0 
26.9 
24.1 
33.0 
 
16.7 
29.2 
24.0 
30.1 
 
16.1 
25.7 
24.5 
33.8 
 
18.7 
24.7 
24.4 
32.2 
cART regimen at baseline 
    NNRTI 
    PI boosted 
    PI non-boosted 
    Triple nucleoside/Other 
 
35.5 
14.6 
37.0 
13.0 
 
38.7 
12.5 
36.7 
12.1 
 
33.8 
16.6 
40.1 
9.5 
 
33.8 
16.1 
34.9 
15.2 
 
25.2 
20.0 
37.8 
17.1 
No. of  cART regimens √ 
    Median (IQR) 
 
2 (1-5) 
 
2 (1-4) 
 
2 (1-4) 
 
3 (1-5) 
 
3 (2-6) 
Years on cART * 
    Median (IQR) 
 
3.9 (0.6 - 
6.7) 
 
3.1 (0.5 - 
6.5) 
 
4.0 (0.9 – 6.4) 
 
4.7 (1.2 – 7.0) 
 
5.4 (2.9 – 7.1) 
Years since HIV diagnosis  
    Median (IQR) 
 
7.9 (3.0-
13.6) 
 
6.9 (2.2-
12.8) 
 
7.9 (3.6-13.1) 
 
9.5 (4.0-14.5) 
 
10.6 (6.0-15.4) 
#   9 years of mandatory schooling or less 
√  Number of cART regimens at baseline, including the current one, taken while registered in the cohort 
*  For those cART taken while registered in the cohort 
IQR=interquartile range, MSM=men who have sex with men, IDU=intravenous drug use, cART=combined antiretroviral 
therapy, NNRTI= non-nucleoside reverse transcriptase inhibitors, PI = protease inhibitors 
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analyses of naive and pre-treated patients, only the CIs widened and the predicted group 
membership changed. Compared to the model with all patients, naive patients were more likely to 
belong to the group with worsening adherence (27.0%), and less likely to belong to the poor 
adherence (6.9%). Table 5.1 provides baseline characteristics by group membership from the 
analysis including all individuals. Individuals with consistently poor adherence more often had only a 
basic education, were IDU (less often MSM), were under psychiatric treatment, had legal problems, 
on an NNRTI, on cART for longer, and living with HIV for a longer time. 
 
Figure 5.1 Self-reported missed doses of cART over time since introduction of the adherence 
questionnaire in January 2003. 
 
Of the 42,362 visit pairs, no change in adherence was reported 76.2% of the time with 12.4% 
reported improvements and 11.4% reporting decrements in adherence. Different factors were found 
to be associated with worsening and improving adherence (Table 5.2). In multivariable models 
adjusted for adherence on the first visit of the pair, factors significantly associated with worsening 
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adherence were younger age, basic education, loss of a roommate, starting IDU, increasing daily 
alcohol intake (resulting in categorization in a higher alcohol risk category), starting psychiatric 
treatment, longer time living with HIV, onset of lipodystrophy, and changes of the physician or 
center where the individual was followed. In multivariable models, factors significantly associated 
with improvements in adherence were starting co-medications, changes in the class of cART, and 
regimen simplification (decreases in dosing frequency). Individuals with basic education and those 
on cART for a longer time at baseline were significantly less likely to improve their adherence.  
 
 
Figure 5.2 Trajectories with 95% CIs of adherence groups identified by clustering the number of 
missed doses over time: group 1 = consistently good adherence group, group 2 = steadily worsening 
adherence group, group 3 = steadily improving adherence group, and group 4 = consistently poor 
adherence group. The predicted probabilities of group membership are given. 
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Several sensitivity analyses were performed: 1) stratification by gender, 2) stratification by reported 
missed doses at the initial visit of the pair, and 3) removing alcohol from the model due to a large 
number of missing values (data collection began only in 2005). All models returned similar results 
demonstrating the robustness of our results (data not shown). 
 
Table 5.2 Independent predictors of worsening or improving adherence using repeated measures 
logistic regression*  
 
Predictor Worsening adherence Improving adherence 
 OR (95% CI) OR (95% CI) 
Sociodemographic-related factors   
     Age (per 5 years) § 0.92 (0.89-0.95) 1.05 (0.99-1.10) 
     Male gender  0.91 (0.81-1.02) 0.86 (0.72-1.03) 
     Caucasian  0.98 (0.84-1.14) 0.82 (0.65-1.05) 
     Basic education #  1.16 (1.03-1.31) 0.82 (0.68-0.99) 
     Began living alone √ 1.30 (1.06-1.60) 0.84 (0.61-1.15) 
     Ended a stable partnership √ 1.06 (0.86-1.32) 0.98 (0.72-1.33) 
Patient-related factors   
     Started IDU √ 1.89 (1.30-2.77) 1.11 (0.59-2.11) 
     Started drug maintenance program √ 0.78 (0.47-1.29) 0.96 (0.49-1.86) 
     Increase in alcohol intake √‡ 1.25 (1.10-1.43) 0.82 (0.67-1.01) 
     Started smoking √ 1.11 (0.84-1.46) 1.07 (0.70-1.65) 
     Began riskier sex behavior √ 1.09 (0.94-1.26) 1.13 (0.91-1.40) 
     Began psychiatric treatment √ 1.26 (1.04-1.52) 1.08 (0.79-1.48) 
     Release from prison release or  
             resolution of legal issues √  
 
1.24 (0.76-2.03) 
 
0.74 (0.37-1.50) 
Health condition-related factors   
     Hospitalization √ 1.12 (0.95-1.31) 0.85 (0.66-1.09) 
     Started co-medication √ 0.95 (0.73-1.23) 1.95 (1.29-2.94) 
     Time living with HIV (per 5 years) § 1.11 (1.05-1.17) 0.94 (0.87-1.02) 
Treatment-related factors   
     Change in class of cART √ 0.90 (0.72-1.13) 1.48 (1.08-2.04) 
     Decrease in dosing frequency √ 0.86 (0.70-1.05) 1.45 (1.08-1.94) 
     Time on cART (per year) § 0.99 (0.97-1.01) 0.95 (0.91-0.99) 
     Number of previous cART regimens § 1.02 (0.99-1.04) 1.02 (0.97-1.06) 
     Onset of lipodystrophy √ 1.21 (1.00-1.47) 1.09 (0.81-1.46) 
Health system-related factors   
     Change of physician or center √ 1.22 (1.10-1.36) 1.08 (0.91-1.27) 
* Results are from 2 models, one for worsening of and one for improvements in adherence. Both models are adjusted for 
correlation between visit pairs from the same individuals.  Adjusted for reported adherence on first visit (Vi) of the 
consecutive pair     
§ At baseline 
# Nine years of mandatory schooling or less 
√ Changes in the covariate between consecutive visit pairs or since the previous visit 
‡  Increase in daily alcohol consumption so that patient falls into a higher alcohol risk category (as defined by WHO [21]) 
OR = odds ratio, CI = confidence interval, IDU = intravenous drug use, cART=combined antiretroviral therapy 
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Discussion 
We did an in-depth and novel exploration of self-reported adherence to cART over time in 
individuals participating in the SHCS. Self-reported adherence was quite high with individuals 
reporting missing 0 doses of cART on almost 80% of visits. We identified four distinct adherence 
patterns based on almost 50,000 adherence questionnaires. We did a comprehensive and unique 
assessment of the effect of both time fixed and time updated predictors on changes in adherence 
over the 6 year study period.  
These same four adherence patterns (good, improving, worsening, and poor) observed in all patients 
were also detected in a population of only naive patients as well as pre-treated patients.  The 
pattern of consistently good adherence had the highest estimated group membership for all sub-
populations while naive patients were more likely to fall into the worsening adherence pattern than 
pre-treated individuals. There were observed differences in group membership by several baseline 
factors most notably that individuals with a history of psychiatric treatment or legal problems, were 
more often in the poor adherence group. In future work we plan a validation of these adherence 
groups on clinical outcomes. 
Our analysis of changes in adherence included factors from all five dimensions identified by the 
WHO as determinants of adherence [21]. Some of these variables, in particular the social support 
variables, co-medication, and health system factors, have not been studied previously. In addition, 
no other study to our knowledge has included changes in factors as predictors of changes in 
adherence to explore potential triggers for periods of worsening adherence. We could confirm 
several factors found in other studies to be associated with worsening or improving adherence such 
as age [18,20], education [18], IDU [16,18], alcohol intake [16,18], depression [18], taking a PI-based 
regimens [16], and symptoms [16,20]. In addition to these variables, we found loss of a roommate, 
longer time since HIV diagnosis, and health system changes such as disruption of the continuity of 
care by the same physician or hospital were significantly more likely to be associated with reported 
worsening adherence. Newly identified factors significantly associated with improvements in 
adherence were changes in cART class, regimen simplification and starting to take medication for OI, 
CVD, hepatitis C or cancer.  
Our results demonstrate that not only demographic factors such as age, gender, and education 
influence adherence, but short-term changes in factors can impact changes in adherence as well. 
These changes can serve as signals to the clinicians to provide additional adherence support. 
Changes in a patient’s living situation (such as loss of a roommate) or changes to their physician or 
 77 
center of care can signal a loss of social support and lead to lapses in medication taking. It may be 
the challenge of moving house or the difficulty in building a trusting relationship with a new 
physician that impacts adherence behaviour. Changes to regimens with higher daily administration 
frequency or one with known side effects such as lipodystrophy – can all result in worsening 
adherence. These results suggest clinicians need to anticipate the possibility of added stress during 
periods of change for patients and provide additional support during these times.  
The SHCS is a long-standing and well-described prospective cohort that collects a variety of 
information longitudinally in a diverse population of heterosexuals and women, making the results 
generalizable.  This study includes a large sample of HIV-infected individuals followed for up to 6 
years. We have identified a number of new factors that affect adherence and thus impact drug 
failure.  We conducted extensive sensitivity analyses to ensure the robustness of the results. 
A limitation of this study is that our results are based on self-reported adherence provided in an 
interview with a clinician.  These reports can be subject to recall bias or social desirability bias, 
leading to underreporting of non-adherence behavior [26,27]. However, two systematic reviews 
including a large number of observational studies found a robust association between self-reported 
adherence and viral load over varying measures and recall periods [28] and indicated that self-
reported adherence measures can distinguish between clinically meaningful patterns of medication-
taking behaviour [29]. Other information in the SHCS is also collected via self-report, such as sexual 
risk behavior, drug use, psychological and legal problems, which could also result in reporting bias 
due to the sensitivity of these topics. Another limitation is the observational nature of the study 
which can lead to biased results due to unmeasured confounding. In addition, there is likely 
confounding by indication with respect to the choice of cART, especially in groups at risk for 
adherence problems.   
Adherence was found to be improving over time (Figure 5.1), contrary to results from other studies 
[19,20] performed prior to 2001. A more recent study also detected a decreasing trend in adherence 
until 2003 and then adherence started to improve [16]. We can hypothesize that regimen 
simplification in recent years has facilitated improved adherence. It is also likely that introducing 
systematic adherence assessments resulted in increased attention in both patients and clinicians to 
the issue of adherence and therefore led to improvements in adherence. Also, the SHCS is an open 
cohort and the population is changing over time– for example the number of individuals from IDU 
risk group has decreased dramatically over time with a corresponding increase in MSM and 
heterosexuals, groups known to have better adherence. Therefore our results provide unbiased 
measures of associations (but not causation) between covariates and outcome.   
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In conclusion, our results indicate that clinicians should routinely enquire about factors that may 
disrupt regular drug intake such as changes in substance and alcohol use, psychiatric treatment and 
important lifestyle changes including loss of social support. In particular, clinicians should be 
sensitive to the risk of worsening drug adherence when changes in the patient care provider 
relationship are planned. Additional adherence counselling should be provided to patients 
experiencing potentially stressful situations so that they can learn the skills to cope with these 
changes without disruption in their drug intake. Future studies should investigate whether simple 
patient focussed interventions suitable to busy clinical practice, such as routine checking of risk 
factors for changes in regular drug intake identified by this study, may enhance drug adherence and 
reduce risk of treatment failure and drug resistance.  
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Abstract 
 
Background 
 The aim of this study was to explore the predictive value of longitudinal self-reported adherence 
data on viral rebound. 
Methods 
Individuals in the Swiss HIV Cohort Study on combined antiretroviral therapy (cART) with RNA < 50 
copies/ml over the previous 3 months and who were interviewed about adherence at least once 
prior to March 1, 2007 were eligible. Adherence was defined in terms of missed doses of cART (0, 1, 
2 or >2) in the previous 28 days. Viral rebound was defined as RNA >500 copies/ml. Cox regression 
models with time-independent and -dependent covariates were used to evaluate time to viral 
rebound.   
Results 
A total of 2,664 individuals and 15,530 visits were included. Across all visits, missing doses was 
reported as follows: 1 dose 14.7%, 2 doses 5.1%, >2 doses 3.8%, taking <95% of doses 4.5%, and 
missing ≥2 consecutive doses 3.2%. In total, 308 (11.6%) patients experienced viral rebound. After 
controlling for confounding variables, self-reported non-adherence remained significantly associated 
with the rate of occurrence of viral rebound (compared to 0 missed doses: 1 dose, HR 1.03, 95% 
confidence interval (CI): 0.72-1.48; 2 doses, HR 2.17, 95% CI: 1.46-3.25; >2 doses, HR 3.66, 95% CI: 
2.50-5.34). Variables significantly associated with an increased risk of viral rebound irrespective of 
adherence were identified: being on a protease inhibitor or triple nucleoside regimen (compared to 
non-nucleoside reverse transcriptase inhibitor), >5 previous cART regimens, seeing a less 
experienced physician, taking co-medication, and shorter time virally suppressed.  
Conclusions 
A simple self-report adherence questionnaire repeatedly administered provides a sensitive measure 
of non-adherence that predicts viral rebound.  
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Introduction 
Adherence to combined antiretroviral therapy (cART) is fundamental for achieving and maintaining 
viral suppression, preventing drug resistance, and improving survival in HIV-infected individuals [1-
3].  However, there remains no definitive approach to adherence assessment [4,5] and no standard 
definition of non-adherence. Many studies have indicated that high levels of adherence to cART are 
necessary to achieve optimal suppression of HIV-1 RNA [6,7], but the exact level of adherence 
necessary is unknown and likely to vary by cART regimen [8,9]. 
The ongoing debate on the best way to measure and utilize adherence data is fueled by the need for 
simple and accurate methods to measure adherence to cART in routine clinical practice. 
Standardized measurement tools are needed as physicians experience difficulties in assessing 
patient adherence to cART accurately [10,11]. Self report of drug adherence offers the primary 
advantages of ease of administration, flexibility and low cost.  However, self-report is subject to 
recall bias.  Patients’ reporting of non-adherence has been found to be credible [12,13] but their 
estimate of the degree of adherence is often inaccurate [14], overestimating adherence by 10-20% 
compared to electronic monitoring (EM) [15,16].  Despite these disadvantages, two recent 
systematic reviews both including a large number of observational studies found a robust 
association between self-reported adherence and viral load over varying measures and recall periods 
[5], and indicated  that self-reported adherence measures can distinguish between clinically 
meaningful patterns of medication-taking behaviour [17].  
Although other methods such as pill count and prescription refill have been used successfully to 
measure adherence, these methods are not practical over the long-term, suffer from 
implementation problems and do not provide detailed information such as drug holidays. Although 
EM provides an accurate, detailed measure of adherence, it is not practical for routine use and 
would be better used to educate naïve individuals starting therapy or as an aid for individuals with 
known adherence problems. 
Most observational studies - independent from the measurement method for adherence – suffer 
from additional shortcomings. The majority of studies are of cross-sectional design, precluding the 
ability to make causal inferences. Longitudinal studies with multiple adherence measurements in the 
same patient often summarize adherence behaviour over the whole study period leading to a loss of 
efficiency and information; this approach also ignores the important dynamic of adherence changes 
over time [18,19]. 
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In a previous cross-sectional analysis of the Swiss HIV Cohort Study (SHCS) we showed a strong linear 
relationship between self-reported non-adherence by interview over the previous 28 days and 
optimal viral suppression [20]. The goal of this study of HIV-infected individuals with complete viral 
suppression on cART was to use all the information from repeatedly applied questionnaires in a 
time-updated analysis to test whether the two-item questionnaire of the SHCS predicts viral 
rebound. 
 
Methods 
Patients  
The SHCS is a prospective cohort study with continuing enrollment of HIV-infected individuals aged 
16 years or older. Visits take place every 6 months at 7 outpatient clinics from participating HIV 
centers, associated hospitals or specialized private practices. Eligible individuals were: actively 
enrolled in the SHCS, on cART, virally suppressed (HIV-1 RNA≤50 copies/ml) for at least 3 months 
prior to baseline and had at least one follow-up HIV-1 viral load measurement. Baseline is taken as 
the official cohort visit prior to completion of their first adherence questionnaire.    
Outcome definition 
The primary endpoint of the study was time to virologic rebound defined as time to HIV-1 RNA>500 
copies/ml. Confirmed viral rebound (two consecutive RNA>500 copies/ml) was also considered as an 
outcome.  The majority of recent treatment guidelines suggest that intermittent viraemia (isolated 
HIV-1 RNA levels between 50 and 500 copies/ml) are often of no clinical consequence, but 
consecutive rebounds of HIV-1 RNA>500 copies/ml can be associated with virologic failure [21].  
Adherence definitions 
An adherence questionnaire was introduced into the follow-up of the SHCS in July 2003 and has 
been previously described [20]. Individuals were asked two questions by their clinician: (i) How often 
did you miss a dose of your medication in the last 4 weeks? Daily, more than once a week, once a 
week, once every two weeks, once a month, never; and (ii) Did you miss more than one dose in a 
row? Yes, no. The questionnaire has been validated in a study comparing the European HIV 
treatment questionnaire, a visual analogue scale, and  EM [22]. Using virologic failure as the gold 
standard, the SHCS adherence questionnaire in the validation study performed slightly better than 
either EM or a combination of the adherence questionnaire and a VAS with a sensitivity of 88% and a 
specificity of 79%. In this study, non-adherence was categorized into the number of missed doses: 0, 
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1, 2, and >2. Several methods for handling missing adherence data were considered: missing data 
was excluded from the analysis, the last non-missing observation was carried forward (LOCF), 
‘missing’ was added as a category of missed doses, and missing data was replaced by an indicator of 
non-adherence (missing 2 doses).     
Covariate definitions 
Covariates that were potential confounders of the relationship between adherence and viral 
rebound were considered for inclusion in the analysis. The following time-independent covariates 
were measured at baseline: gender, age, prior intravenous drug use, CD4+ T-cell count (cells per 109 
/l), duration of viral suppression, prior AIDS diagnosis, number of previous cART regimens (≤5 or >5), 
physician experience (defined as the number of HIV-infected patients in the SHCS previously treated 
by a physician at the time of the patient’s baseline visit), and time on cART. The following time-
dependent (i.e., time-updated) covariates were measured at each follow-up visit:  having a stable 
partner, taking co-medications (for risk factors for cardiovascular disease [dyslipidaemia, diabetes, or 
hypertension], opportunistic infections [OI], hepatitis C, or cancer), hospitalization, and current cART 
(non-nucleoside reverse transcriptase inhibitor [NNRTI], non-boosted protease inhibitor [PI], 
boosted PI, triple nucleoside). An interaction between adherence and cART regimen and dosing 
frequency was tested for inclusion in the model. 
Statistical methods 
A time-to-event analysis was performed using a Cox proportional hazards model to study the effects 
of both time-independent and time-dependent explanatory variables on the event incidence.  Events 
were defined as the first date where HIV-1 RNA was >500 copies/ml.  For individuals who did not 
experience an event, follow-up was censored on March 1, 2007, on the date when cART was stopped 
for ≥45 days, the date of loss to follow-up or death.  The association between explanatory variables 
and viral rebound were assessed by using hazard ratios (HR) and 95% confidence intervals (CI); HRs 
>1 indicate a covariate is positively associated with the event probability.  Variables known to be 
confounders were automatically considered for inclusion in the final adjusted model while all other 
previously untested variables were included only if there was some evidence of an association 
(p<0.25) in unadjusted models. Following the fit of the multivariable model, the importance of the 
variable as a confounder (as measured by its impact on the hazard ratio of the other variables) was 
verified or the variable was eliminated from the final model. All analyses were carried out with SAS 
v9.1 (SAS Institute Inc., Cary, NC, USA). The manuscript was written to comply with STROBE 
guidelines for observational studies [23]. 
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Sensitivity analyses  
As an additional validation of the adherence measurement, several additional measures of non-
adherence were calculated. To explore the impact of previous reports of non-adherence, we 
constructed an indicator of the highest number of reported missed doses (0, 1, 2, or >2) at each time 
point for all follow-up visits including the current visit. To make our results comparable with other 
studies, non-adherence was calculated as taking <95% of doses.  However, as we do not collect 
adherence information as a percentage of doses taken, this definition had to be approximated based 
on the number of missed doses in the previous 28 days and the dosing frequency of the current cART 
regimen. For example, an individual on a once-daily regimen who missed two doses in the previous 
28 days was calculated to have taken <95% of doses (26/28=92.8%). In addition, we tested whether 
missing at least two consecutive doses of cART was an independent predictor of virologic failure. 
 
Results 
In total, 7,539 patients were actively registered in the SHCS between 1 July 2003 and 1 March 2007. 
Of these, 5368 had at least one follow-up visit within 1 year of the baseline visit where they 
completed an adherence questionnaire and had corresponding laboratory data recorded. Of these, 
2,704 were excluded for several reasons: not virally suppressed (HIV-1 RNA≥50 copies/ml) for a 
minimum of 3 months (n=2,689), off treatment at baseline visit (n=10), cART-naïve (n=2), no follow-
up HIV-1 RNA values (n=2), and stopped treatment 1 day after baseline (n=1).  A total of 2,664 
patients with 15,530 visits were included in the analysis. The total prospective follow-up until the 
event date or until the censoring date for those without an event was 7,693 person-years, with a 
median individual follow-up time of 3.3 years (interquartile range [IQR] 2.5-3.6). The median number 
of follow-up visits after baseline was 6 (range 1-8). A total of 308 (11.6%) patients experienced viral 
rebound during the study period, with a median time to viral rebound of 16 months (IQR 9.5-29). 
Baseline characteristics of the analysis population are displayed in Table 5.1. Over all visits in the 
study period, missing doses were reported as follows: 1 dose 14.7%, 2 doses 5.1%, >2 doses 3.8%, 
taking <95% of doses 4.5%, and missing ≥2 consecutive doses 3.2%. A total of 49% of patients 
reported a change in the number of missed doses over the study period. Individuals were mostly on 
twice daily regimens (87.1%) with only marginal numbers on either once daily (10.7%) or three times 
daily regimens (2.2%); however the number of individuals on once daily regimens was increasing 
over the study period with a corresponding decrease in both those on twice daily and three times 
daily regimens. 
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Table 5.1 Baseline characteristics of individuals included in the analysis 
Characteristic  
Total – n (%) 2664 (100) 
Median age, years [IQR] 42 [37-48] 
Male gender – % 70.8 
Past or present intravenous drug use – % 22.9 
Smoker* - % 46.4 
Stable partnership* - % 60.8 
Living alone* - % 39.9 
Previous AIDS diagnosis - % 28.6 
Hospitalization* - %  7.7 
Experience of physician ± - median [IQR] 170 [102-294] 
CD4 count (cells per 109/l )  
    Median [IQR] 
    < 200 (%) 
    200 – 349 (%) 
    350 – 499 (%) 
     500 (%) 
 
478 [331-677] 
8.6 
19.0 
25.1 
47.3 
Current cART regimen - % 
    NNRTI 
    PI non-boosted 
    PI boosted 
    Triple nucleoside and other 
 
34.8 
21.9 
24.5 
18.8 
Number of previous cART regimens 
   Median [IQR] 
 
3 [2 - 5] 
Time on cART (years) 
   Median [IQR] 
   Mean [SD] 
 
5.7 [3.4 – 7.3] 
5.6 [2.7] 
Time optimally virally suppressed (years) 
   Median [IQR]  
   Mean [SD] 
 
2.4 [1.1 – 4.3] 
2.7 [1.8] 
*   In the previous 6 months 
¶   In the previous 28 days 
±   Number of HIV-infected patients treated by a physician at the time of the patient’s baseline visit 
SD=standard deviation, IQR=interquartile range, cART=combined antiretroviral therapy, PI=protease 
inhibitors, NNRTI=non-nucleoside reverse transcriptase inhibitor  
 
Adherence data was missing for 452 (3.3%) visits and the rate of missing data steadily increased over 
time (1.3% to 5.3%). All four methods of replacing missing data were explored in unadjusted Cox 
models. All methods yielded similar results and only the HR for missing >2 doses was slightly lower 
but still highly significant with LOCF, known to be a conservative method for handling missing data. 
In addition, when missing adherence information was included as a category of non-adherence, 
individuals with missing adherence data were significantly more likely to experience viral rebound 
than individuals with no reported missed doses with an estimate similar to that of missing two doses 
(HR 2.39, 95% CI 1.62-3.51). Although there is some indication that missing information is 
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informative, individuals with missing adherence data was excluded from the final analysis as the 
overall percentage of missing was very small.  
The proportion of individuals experiencing viral rebound increased with increasing number of missed 
doses. In addition, with two or more reported missed doses, there were differences in the rate of 
viral rebound by class of ART (Figure 5.1).  
 
Figure 5.1 Percentage of patients with viral rebound (RNA>500 copies/ml) by self-reported missed 
doses and current class of cART regimen 
 
The results of the Cox proportional hazards models of the association between time-updated non-
adherence and virologic rebound are provided in Table 5.2. In unadjusted models, two or more 
missed doses were significantly associated with the risk of viral rebound when compared to perfect 
adherence (1 dose, HR 1.11, 95% CI 0.78-1.57; 2 doses, HR 2.34, 95% CI 1.57-3.50; >2 doses, HR 4.04, 
95% CI 2.78-5.87). After controlling for potential confounding variables, self-reported non-adherence 
remained significantly associated with the rate of occurrence of viral rebound (compared to 0 missed 
doses: 1 dose, HR 1.03, 95% CI 0.72-1.48; 2 doses, HR 2.17, 95% CI 1.46-3.25; >2 doses, HR 3.66, 95% 
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CI 2.50-5.34). Five variables significantly associated with an increased risk of viral rebound 
irrespective of adherence were identified: (i) being on a PI or triple nucleoside regimen (compared 
with a NNRTI regimen), (ii) having experienced >5 previous cART regimens, (iii) seeing a physician 
with less experience, (iv) taking co-medication, and (v) less time with viral suppression at baseline. 
Age, gender, stable partnership, AIDS diagnosis and hospitalization were not significantly associated 
with viral rebound in adjusted models and exhibited no evidence of confounding and therefore were 
excluded from the final analysis. 
 
Table 5.2 Association of baseline and time-updated covariates with the rate of occurrence of viral 
rebound, RNA>500 copies/ml (both confirmed and unconfirmed), using a Cox proportional hazards 
model.  
 
Variables 
Adjusted model 
VR = RNA >500 copies/ml 
(n=308 events) 
Adjusted model 
VR = two consecutive RNA >500 
copies/ml 
(n=102 events) 
HR (95% CI) p-value HR (95% CI) p-value 
Intravenous drug use (current or past) 1.20 (0.92 – 1.57) 0.19 1.15 (0.71 – 1.86) 0.573 
Increases in baseline CD4 cell count of 100 
(cells per 10
9
/l ) 
1.02 (0.98 – 1.07) 0.39 1.02 (0.95 – 1.04) 0.60 
cART regimen  
    NNRTI 
    Non-boosted PI 
    Boosted PI 
    Triple nucleoside/other 
 
Reference 
1.50 (1.04 – 2.17) 
1.53 (1.13 – 2.09) 
1.63 (1.13 – 2.35) 
 
 
0.03 
0.007 
0.01 
 
Reference 
1.23 (0.61 – 2.49) 
1.67 (0.96 – 2.91) 
1.62 (0.82 – 3.23) 
 
 
0.56 
0.07 
0.17 
> 5 previous cART regimens at baseline 1.44 (1.09 – 1.89) 0.009 1.96 (1.23 – 3.11) 0.005 
Physician experience ± (per 100 patients) 0.83 (0.76 – 0.92) <0.001 0.84 (0.71 – 0.99) 0.04 
Co-medication √ 1.44 (1.06 – 1.96) 0.02 2.42 (1.50 – 3.90) <0.001 
Time virally suppressed at baseline (per year) 0.77 (0.71 – 0.83) <0.001 0.82 (0.72 – 0.94) 0.005 
Non-adherence (missed doses):  
    0 
    1 
    2 
  >2 
 
Reference 
1.03 (0.72 – 1.48) 
2.17 (1.46 – 3.25) 
3.66 (2.50 – 5.34) 
 
 
0.86 
<0.001 
<0.001 
 
Reference 
1.25 (0.68 – 2.30) 
1.24 (0.50 – 3.12) 
4.51 (2.47 – 8.24) 
 
 
0.48 
0.64 
<0.001 
±   Number of HIV-infected patients treated by a physician at the time of the patient’s baseline visit   
√   For cardiovascular problems, opportunistic infections, hepatitis C, or cancer  
*   In the previous 28 days 
cART, combined antiretroviral therapy; CI, confidence interval; HR, hazard ratio; PI, protease inhibitor; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; VR, viral rebound 
 
To further explore the effect of co-medication, the indicator of taking any co-medication was 
replaced in turn in the final adjusted model by an indicator of taking co-medication for each 
indication separately. Only medication taken for risk factors for cardiovascular disease showed no 
evidence of effect on treatment failure. Receiving treatment for OI, hepatitis C and cancer were all 
independently associated with an increased hazard for treatment failure, although hepatitis C was 
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only marginally significant. When all four indicators of taking specific co-medication were entered 
simultaneously into the adjusted model, the results remained the same (Table 5.3). 
There is evidence to suggest that missing doses of medication has different implications for 
treatment failure depending on both the class of ART regimen and the dosing frequency of the 
regimen [24-27]. The interaction between missed doses and class of ART regimen was non-
significant and therefore not included in the final model.  With regards to dosing frequency, 
interaction variables for both consecutive missed doses and missed doses were constructed.  
However, due to low numbers of individuals on once daily and three times daily regimens, the HRs 
were not estimable for most categories. The only additional comparisons produced from this 
analysis were between those reporting perfect adherence (over all dosing frequencies) and those 
who reported missing one dose on a once daily regimen (HR 2.82, 95% CI 1.32-6.01) and missing one 
dose on a twice daily regimen (HR 0.91, 95% CI 0.60-1.36).  
 
Table 5.3 Exploring the association of use of any co-medication as well as co-medication use by 
individual indication with the rate of occurrence of viral rebound (unconfirmed RNA>500 copies/ml) 
using Cox proportional hazards model 
 
 
When the outcome was time to confirmed viral rebound (two consecutive RNA>500 copies/ml), the 
adjusted Cox model yielded very similar results to the model with unconfirmed viral rebound (Table 
5.2).  CIs were generally wider and some variables were no longer significant likely due to having 
only one-third of the number of events (102 versus 308).  
 
Variables 
Unadjusted model Adjusted model * 
HR (95% CI) p-value HR (95% CI) p-value 
All co-medication √ 1.52 (1.14 – 2.03) 0.004 1.44 (1.06 – 1.96) 0.02 
Co-medication by indication ±     
     Risk factors for CV disease # 1.07 (0.70 – 1.63) 0.75 1.01 (0.64 – 1.59) 0.97 
    Opportunistic infections 2.17 (1.50 – 3.14) <0.001 1.80 (1.20 – 2.69) 0.004 
    Hepatitis C 1.69 (0.90 – 3.17) 0.10 1.73 (0.91 – 3.29) 0.09 
    Cancer 4.13 (1.32 – 12.88) 0.01 3.20 (1.01 – 10.17) 0.05 
* adjusted for IV drug use, baseline CD4 cell count, ART regimen, number of previous ART regimens, physician experience, 
time virally suppressed at baseline, and non-adherence (see Table 5.2). 
√ For risk factors for cardiovascular disease, opportunistic infections, hepatitis C, or cancer 
± The indicator for taking any co-medication was replaced in the adjusted model by the four separate indicators of taking 
co-medication for the individual indication. 
# For dyslipidemia, hypertension, or diabetes 
CV, cardiovascular; HR, hazard ratio; CI, confidence interval 
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In sensitivity analyses, we explored whether these results could be validated when different levels of 
non-adherence were considered. The time-updated indicator of the highest number of missed doses 
up to the point of the current follow-up visit provided similar results to the primary analysis although 
the hazard ratios were lower (1 dose, HR 0.73, 95% CI 0.53-1.02; 2 doses, HR 1.51, 95% CI 1.08-2.11; 
>2 doses, HR 2.44, 95% CI 1.78-3.34). Taking <95% of doses of cART in the previous 4 weeks was 
significantly associated with viral rebound as a time-updated predictor in an adjusted model (HR 
3.18, 95% CI 2.20-4.60). The estimates for covariates were almost identical to the primary analysis 
(data not shown). Missing two or more consecutive doses of cART in the previous 4 weeks was found 
to be an independent predictor of time to viral rebound in an adjusted model (HR 3.53, 95% CI 2.42-
5.15). Effect estimates and CIs for covariates were also almost identical to those in the primary 
analyses (data not shown). 
 
Discussion 
This study demonstrates that in HIV-infected individuals on cART with prior viral suppression, self-
reported missed doses are associated with a higher risk of virologic failure. Increasing number of 
missed doses in the previous 4 weeks was associated with an increasing hazard of virologic failure. 
Missing two or more consecutive doses of cART was reported on fewer than 4% of visits but was 
associated with 3.5 times increased risk of viral failure.  
Although several other studies have collected longitudinal self-reported adherence information 
[1,28-30], we know of no other study that has used time-updated measurements of self-reported 
adherence to predict viral rebound. With this approach, we avoid the loss of information inherent in 
analyses that summarize adherence information over time.  In addition, an individual’s adherence 
pattern is allowed to vary in a dynamic way which is a better reflection of reality and is supported by 
the finding that almost 50% of individuals reported a change in the number of missed doses over the 
study period. This approach gave a precise and sensitive estimate of the risk of viral rebound by 
missed doses after adjusting for a comprehensive list of potential confounders. Also important to 
note was that we considered several additional definitions of non-adherence in sensitivity analyses 
and our results were highly consistent, with similar effect estimates for all confounders.  
The simplification of regimens will certainly have a positive impact on adherence and treatment 
outcomes [26,31], but the introduction of an increasing number of once daily regimens will not 
eliminate concerns about adherence to ART. We found evidence that individuals missing only one 
dose of ART on a QD regimen are at 2.8 times increased risk of treatment failure, whereas those 
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missing one dose on a twice daily regimen showed no increased risk. Although there were not 
sufficient numbers on either once daily or three times daily regimens to fully explore the effect of an 
interaction between missed doses and dosing frequency, these findings should be explored further 
and incorporated into future adherence definitions. 
This study considered a large number of important confounders: clinical factors (including the 
previously unstudied effect of co-medication) as well as psychosocial factors such as stable 
partnership and health system factors such as physician experience. Independent of reported 
adherence to cART, several factors were significantly associated with an increased hazard of viral 
rebound. Individuals on NNRTI regimens were at a decreased risk of virologic failure compared with 
individuals on all other regimens, although previous studies have shown varied results [1,9,32].  
Similar to other studies where suboptimal HIV management was associated with physicians who 
care for only a few HIV-infected patients [33-35], we found a significant association between lower 
physician experience and higher incidence of virologic failure, although a recent study did not 
confirm these findings [32]. Individuals taking any co-medication for the treatment of risk factors for 
cardiovascular disease, OI, hepatitis C, or cancer had a 1.4 times higher risk of viral rebound (see 
Table 5.3). Additional analyses suggested that this effect is largely driven by the taking of medication 
for OI, hepatitis C, and cancer. Treatment for some OI, hepatitis C, and cancer may result in side 
effects, drug interactions and potential treatment interruption and thus risk of virological failure. 
The lack of an effect from co-medication taken for cardiovascular risk factors is encouraging news as 
an increasing number of treated individuals will likely be at risk for ART-induced metabolic disorders 
[36]. Our findings suggest that the condition of the co-morbidity and its treatment and not 
necessarily the additional pill burden of co-medication, are related to treatment failure The effect of 
co-medication has not been studied previously and our finding has important implications for the 
management of an ageing HIV-infected population in need of both drug treatment for HIV and other 
chronic conditions.   
Our data confirm recent evidence suggesting that different classes of cART regimens can require 
varying levels of adherence to maintain viral suppression [4,9]. However, previous studies did not 
include individuals on either boosted PI regimens or triple nucleoside regimens. Individuals on 
NNRTIs and triple nucleosides had lower rates of viral rebound than those on PI regimens with 
similar levels of self-reported adherence (Figure 1). It has been suggested that boosted PI regimens 
may provide forgiveness as well [37,38], however we did not find evidence to support this. This 
could be related to a selection bias with individuals with more treatment experience and greater 
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adherence problems being placed on boosted PIs due to higher resistance barrier or because of 
concerns related to drug interactions, for example, with methadone.  
The rate of missing adherence information increased in proportion to the length of time patients 
were under follow up. As the adherence questionnaire is administered by interview with the 
clinician, this is suggestive of several potential problems.  It is possible the clinician has assumed to 
know the adherence of an individual from past information, although we know from our data and 
others that adherence is a dynamic process. Another issue could be that with the focus of health 
care on acute illnesses and with only short consultation times, physicians might only have time to 
discuss clinical aspects of a patient’s care and therefore behavioral aspects, such as adherence, 
might be given a lower priority.  Regardless of the reasons behind this finding, it is extremely 
important that clinicians find a way to address the adherence of their patients as part of their regular 
follow-up.  
Our data has several limitations. As discussed above, patients are asked about their adherence by 
their clinician, and therefore may be reluctant to admit non-adherence. However, previous studies 
have failed to find a relationship between self-report and social desirability bias [15-16] and one 
study even found that anonymous surveys increased individuals’ reluctance to disclose non-
adherence [17]. We cannot, however, rule out the possibility that changing the mode of 
administration of the questionnaire would minimize potential social desirability bias and provide 
more accurate responses. Second, missing adherence information was excluded from the analysis 
leading to a loss of information.  However, several other methods of handling missing data provided 
consistent results. An in-depth study into adherence patterns may reveal a more meaningful way to 
impute adherence information for these patients, but it is beyond the scope of this study. Third, our 
results are limited to virally suppressed individuals on cART and therefore the effect of adherence on 
viral load for those who are not suppressed is unknown. 
In conclusion, our simple two-item questionnaire, which is easy to implement in routine clinical 
practice, is an independent predictor for future viral failure in individuals with well-suppressed viral 
load. Even though self-report is known to overestimate adherence and suffers from a ceiling effect 
[14,16,39], the questionnaire was sensitive enough to detect both the increased risk of missing one 
dose of ART on a once daily regimen and some level of forgiveness in twice daily regimens. 
Adherence should be monitored continuously and systematically in all HIV-infected individuals on 
cART.  Self-report provides the most practical approach and, our instrument, with only two 
questions, provides a sensitive indicator of future virologic failure. These results warrant further 
investigation in other populations and cultural settings. 
 94 
Acknowledgements 
Contributors: TR Glass, S De Geest, and HC Bucher designed the study and interpreted the results. TR 
Glass did the statistical analysis. R Weber, PL Vernazza, H Furrer, E Bernasconi, M Cavassini, B 
Hirschel, M Battegay were responsible for patients recruitment and clinical assessment, M 
Rickenbach was involved in data management. The paper was written by TR Glass, HC Bucher, and S 
De Geest and reviewed by all other contributors. 
The members of the Swiss HIV Cohort Study are M. Battegay, E. Bernasconi, J. Böni, H. Bucher, 
Ph. Bürgisser,  S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi, P. Erb,  M. Fischer, M. Flepp, 
A. Fontana, P. Francioli (President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011- 
Lausanne), H. Furrer (Chairman of the Clinical and Laboratory Committee), M. Gorgievski, 
H. Günthard, H. Hirsch, B. Hirschel, I. Hösli, Ch. Kahlert, L.  Kaiser, U. Karrer, C. Kind, Th. Klimkait, 
B. Ledergerber, G. Martinetti,  B. Martinez, N. Müller, D. Nadal,  M. Opravil, F. Paccaud, G. Pantaleo, 
M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the Mother & Child Substudy), 
P. Schmid, D. Schultze, J. Schüpbach, R. Speck, P. Taffé, P. Tarr, A. Telenti, A. Trkola,  P. Vernazza 
(Chairman of the Scientific Board), R. Weber, S. Yerly. 
Source of funding:  
This study has been financed in the framework of the Swiss HIV Cohort Study, supported by the 
Swiss National Science Foundation. (Grant no 3347-069366).  TR Glass and HC Bucher are funded by 
grants from santésuisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. The funders had 
no input into the design and conduct of the study; collection, management, analysis, and 
interpretation of the data; or preparation, review, or approval of the manuscript. 
Conflict of interests:  None 
 
 
 
 
 
 
 95 
References 
 1.  Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported 
adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients 
initially responding to HAART. Antivir.Ther. 2004; 9:291-6. 
 2.  Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active 
antiretroviral therapy on survival in HIV-infected patients. J.Acquir.Immune Defic.Syndr. 
2002; 30:105-10. 
 3.  Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent a 
 accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-32. 
 4.  Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor 
therapy can lead to viral suppression. Clin.Infect.Dis. 2006; 43:939-41. 
 5.  Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy 
adherence: A review with recommendations for HIV research and clinical management. AIDS 
Behav. 2006; 10:227-45. 
 6.  Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes 
in patients with HIV infection. Ann.Intern.Med. 2000; 133:21-30. 
 7.  Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is 
predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-8. 
 8.  Bangsberg DR. Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: 
The Past, the Present, and the Future. AIDS Behav. 2006. 
 9.  Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic 
outcomes for patients treated with nonnucleoside analogues or protease inhibitors. 
Clin.Infect.Dis. 2005; 40:158-63. 
10.  Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to 
combination antiretroviral therapy? J.Gen.Intern.Med. 2002; 17:1-11. 
11.  Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing 
adherence and outcomes with newly initiated antiretroviral therapy. AIDS 2002; 16:1835-7. 
12.  Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV 
antiretroviral therapy. J.Acquir.Immune.Defic.Syndr. 2001; 26:435-42. 
13.  Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV 
protease inhibitors. Ann.Intern.Med. 2001; 134:968-77. 
14.  Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more 
accurately then perfect adherence? AIDS Care 2000; 12:405-8. 
15.  Wagner G, Miller LG. Is the influence of social desirability on patients' self-reported adherence 
overrated? J.Acquir.Immune.Defic.Syndr. 2004; 35:203-4. 
 96 
16.  Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via 
electronic drug monitoring and self-report: an examination of key methodological issues. 
AIDS Behav. 2007; 11:161-73. 
17.  Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection 
and virologic treatment response: a meta-analysis. J.Acquir.Immune.Defic.Syndr. 2005; 
38:445-8. 
18.  Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to 
antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-
infected persons in clinical trials. Clin.Infect.Dis. 2002; 34:1115-21. 
19.  Carrieri P, Cailleton V, Le M, V, et al. The dynamic of adherence to highly active antiretroviral 
therapy: results from the French National APROCO cohort. J.Acquir.Immune.Defic.Syndr. 
2001; 28:232-9. 
20.  Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral 
therapy in HIV-infected patients: the Swiss HIV Cohort Study. J.Acquir.Immune.Defic.Syndr. 
2006; 41:385-92. 
21.  Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 
recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-43. 
22.  Deschamps AE, De Geest S, Vandamme A, et al. Diagnostic value of different adherence 
measures using electronic monitoring and virological failure as gold standard. Under review 
2007. 
23.  STROBE Group. Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE). http://www.strobe-statement.org/ . 2005. 2-8-2007.  
24.  Moore DM, Hogg RS, Yip B, et al. Regimen-dependent variations in adherence to therapy and 
virological suppression in patients initiating protease inhibitor-based highly active 
antiretroviral therapy. HIV.Med. 2006; 7:311-6. 
25.  Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-
infected patients on antiretroviral therapy: self-report of the relative importance of multiple 
attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. 
J.Acquir.Immune.Defic.Syndr. 2004; 36:808-16. 
26.  Munsiff, A., Byrne, S., Kadakia, H., and Boyle, B. Once daily HAART achieves more durable 
virologic suppression than twice daily HAART in an ambulatory clinic, urban cohort. The 3rd 
IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005, Rio de Janeiro, Brazil. 
WePe12.2C14. 
27.  Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected 
patients attending a public, urban clinic in Kampala, Uganda. Clin.Infect.Dis. 2006; 42:252-9. 
28.  Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active 
antiretroviral therapy on immuno-virological response: a 3-year follow-up study. 
Antivir.Ther. 2003; 8:585-94. 
29.  Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected 
patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9. 
 97 
30.  Nieuwkerk P, Gisolf E, Sprangers M, Danner S. Adherence over 48 weeks in an antiretroviral 
clinical trial: variable within patients, affected by toxicities and independently predictive of 
virological response. Antivir.Ther. 2001; 6:97-103. 
31.  Ammassari, A., Cozzi-Lepri, A., Trotta, M. P., et al. Treatment complexity and risk of virological 
rebound in persons receiving cART. 14th Conferences on Retroviruses and Opportunistic 
Infections. February 25-28, 2007, Los Angeles, USA. 522. 
32.  Gross R, Yip B, Re VL, III, et al. A simple, dynamic measure of antiretroviral therapy adherence 
predicts failure to maintain HIV-1 suppression. J.Infect.Dis. 2006; 194:1108-14. 
33.  Landon BE, Wilson IB, McInnes K, et al. Physician specialization and the quality of care for 
human immunodeficiency virus infection. Arch.Intern.Med. 2005; 165:1133-9. 
34.  Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and 
enhanced adherence to prescription refill. Antivir.Ther. 2003; 8:471-8. 
35.  Wood E, Hogg RS, Yip B, et al. Is there a baseline CD4 cell count that precludes a survival 
response to modern antiretroviral therapy? AIDS 2003; 17:711-20. 
36.  Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of 
myocardial infarction. N.Engl.J.Med. 2003; 349:1993-2003. 
37.  Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin.Infect.Dis. 2006; 
43:942-4. 
38.  Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving 
lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression 
despite adherence rates less than 95%. J.Acquir.Immune.Defic.Syndr. 2007; 45:4-8. 
39.  Kimmerling M, Wagner G, Ghosh-Dastidar B. Factors associated with accurate self-reported 
adherence to HIV antiretrovirals. Int.J.STD AIDS 2003; 14:281-4. 
 98 
  
 99 
Chapter 7: Causal modeling of observational data 
Introduction 
In a randomized controlled trial (RCT), individuals are assigned to the exposure or treatment group 
at random and this ensures that members of each exposure group are representative of the study 
population, a concept called exchangeability. In a well-designed RCT, the causal effect of exposure 
on outcome can be estimated. Observational studies, on the other hand, can estimate only the 
associational effect of exposure on outcome due to confounding. Confounding is a bias that occurs 
when the exposure and the outcome share a common cause. This bias is the primary disadvantage of 
observational studies and can be thought of as a lack of exchangeability among exposed and 
unexposed. For example, we would like to assess the impact of non-adherence on mortality in HIV-
infected individuals in Swiss HIV Cohort Study (SHCS).  Because adherence behavior is not randomly 
assigned, the effect of non-adherence on outcome is likely confounded by other factors. For 
example, one can imagine that injecting drug use (IDU) can increase both the risk of adherence 
problems and the risk of death. Standard methods to adjust for confounding include stratification, 
for example using Mantel-Haenszel methods, or using regression methods that include both the 
exposure and the confounder as covariates in the model. Assuming exposure does not vary with 
time, it is possible to use these standard approaches to estimate the causal effect of exposure on 
outcome in an observational study if all confounders are correctly measured and adjusted for in the 
analysis.  However, this assumption of no unmeasured confounding can not be tested and is unlikely 
to be true.  
When the exposure can change over time, the usual approach to estimate the effect of non-
adherence on survival would be to model the hazard of failure at a given time as a function of past 
exposure history using a time-dependent Cox proportional hazards model.  However since the 
exposure varies with time, the confounders can also vary with time. Even if one further adjusts for 
past covariate history, these standard approaches will produce biased effect estimates [1] when 1) 
there is a time-dependent covariate that is a predictor of outcome and also predicts subsequent 
exposure and 2) past exposure history predicts the risk factor [2-4]. Covariates satisfying condition 1 
are considered time-dependent confounders. As discussed above, IDU is a confounder of the 
relationship between non-adherence and mortality. Since IDU can change over time, it is called a 
time-dependent confounder. Variables that meet conditions 1 and 2 are time-dependent covariates 
that are simultaneously confounders and intermediate variables (on the causal pathway between 
exposure and outcome). For example, class of combined antiretroviral therapy (cART) is both a risk 
factor for mortality and a predictor of adherence. In addition, prior adherence can influence what 
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future type of cART is selected for the patient due to either resistance or concerns about future 
adherence problems.  Standard regression methods would suggest adjusting for class of cART by 
including it in the model. However since class of cART is on the causal pathway from non-adherence 
to mortality, it should not be included in the regression model if it is of interest to estimate the total 
or overall causal effect of exposure. To better illustrate the problem, we have constructed a directed 
acyclic graph (DAG), useful for depicting causal structure in epidemiologic settings (Figure 7.1). 
Arrows can be interpreted as direct causal effects. 
 
Figure 7.1 Causal graph for time-dependent exposure and confounders. At represents the exposure 
at time t, Lt is the measured confounders at time t, and Y is the outcome. 
 
 
Causal model estimators 
There are several common types of estimators of causal models: the inverse-probability-of-
treatment-weights (IPTW) [1, 5], g-estimators [6, 7], targeted maximum likelihood estimation (TMLE) 
[8, 9], and double-robust (DR) methods [10]. Only IPTW and g-estimation will be discussed in further 
detail here.  
Inverse-probability-of-treatment-weights  estimators 
The bias in observational studies comes from two sources: confounding as discussed above, and 
selection bias due to loss to follow-up.  IPTW estimation views the problem of confounding as one of 
biased sampling. In observational data, certain types of people are likely over- or under-represented 
in the different exposure groups. The IPTW estimator creates a new weighted data set, which has 
the same properties as if the exposure had been randomized. In an unweighted regression model, all 
participants are essentially given a weight of 1, whereas in a marginal structural model using IPTW 
L0 L1
A0 A1 Y
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each individual is assigned a weight at each time point that depends on the likelihood of their 
exposure status given their covariates. In our study, an individual will be assigned a weight that is 
larger than 1 if their observed adherence is rare given their covariates and smaller than 1 if their 
observed adherence is common given their covariates. The average of the weights should be equal 
to one; otherwise this is an indication of a violation of the model assumptions. 
The formula for the stabilized weights is given by 
         
                                     
                                          
      
   
 
where A(k) is a subject’s exposure at time k,  V is a vector of time-independent baseline covariates, 
and       is a vector of time-dependent covariates satisfying condition 1 and 2 discussed above. 
Overbars are used to represent the history of a covariate, so                           is a 
subject’s exposure history up to time t. The numerator of the weights is informally the probability 
that a subject received his own observed treatment at time k conditional on his past treatment 
history and baseline covariates. The denominator further adjusts for past time-dependent prognostic 
factor history (V is included in L(0)).   
These weights are called ‘stabilized’ weights. The goal of stabilization is to minimize the difference 
between the numerator and denominator of the weights such that what remains is a reflection of 
the confounding due to the time-updated covariates in      . However, the result of this stabilization 
means that the weighting creates a pseudopopulation in which exposure is randomized only within 
levels of the covariates in V. For this reason, the baseline covariates must be included in the marginal 
structural model as there may still be confounding due to V. The causal effect estimate then assumes 
the effect is constant across levels of V. One can test whether this is true by adding product (or 
interaction) terms to the marginal structural model.   
‘Nonstabilized’ weights replace the numerator by 1 and can also be used. Although in most cases the 
use of nonstabilized weights should not affect the consistency of the estimate, the variation in 
nonstabilized weights, especially when the exposure is time-updated, can be very large and result in 
a highly variable estimate and a non-normal sampling distribution. In addition, stabilized weights 
generally yield a 95% confidence interval (CI) that is more efficient and has actual coverage rates 
closer to 95% [2, 11]. 
So far we have assumed there was no drop out or censoring by the end of follow-up. Censoring can 
occur in both RCT and observational studies and can induce a bias in the estimate of the effect of 
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exposure on outcome. Similar to the adjustment for confounding bias described above, censoring 
bias can also be corrected using weights. In the end, the outcome in the uncensored subjects must 
represent the unobserved outcomes in the censored subjects with the same covariate values, i.e. 
there must be exchangeability between censored and uncensored individuals. 
The weights to adjust for censoring can be estimated by 
   
      
                                          
                                                      
 
   
 
where C(k) is a censoring indicator that is 1 if a subject is right-censored by time k and 0 otherwise. 
These weights are informally the ratio of a subject’s probability of remaining uncensored up to time 
t, calculated as if there had been no time-dependent determinants of censoring except past 
treatment history, divided by the subject’s conditional probability of remaining uncensored up to 
time t.  
The product of the stabilized weights for confounding and censoring, swi(t) x swi
†(t), form the 
weights used in the final marginal structural model. The denominator is informally the probability 
that an individual has his observed treatment and censoring history through time t. Weighting the 
model by the stabilized weights will produce a consistent estimate of the causal effect of exposure 
on outcome assuming the measured covariates are sufficient to adjust for both confounding and 
selection bias due to loss to follow-up.  
G-estimators   
Analyses using g-estimation generalizes and improves upon analyses based on the G-computation 
and G-null test [7, 12]. Causal models using g-estimation will estimate the causal effect of adherence, 
for example, by calculating the difference in mortality that would have been observed if the entire 
study population would have been adherent versus if the entire study population would have been 
non-adherent. These theoretical outcomes are referred to as ‘counterfactuals’ because it is only 
possible to observe one of the two outcomes for each person. Therefore the counterfactual 
framework has turned the problem of estimating causal effects into a problem of missing data. 
G-estimation is an iterative procedure that involves searching for the causal parameter, ψ, which 
ensures that the unobserved or counterfactual outcome is independent of a subject’s exposure 
given their exposure history and covariates. It is assumed that exposure accelerates failure time by a 
factor of exp(-ψ). In order to find ψ, we need to model the probability of exposure including time-
independent and time-dependent covariates as well as the subject’s observed outcome. For 
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example, with a failure-time exposure variable the following model can be fit with a logistic 
regression relating measured exposure eit at each measurement occasion t to Ui,ψ controlling for all  
confounders xijt 
                         
A series of logistic regression models are fit for a range of different ψ. The G-estimate ψ0 is the value 
of ψ for which the test of α=0, known as a g-test, cannot be rejected with a p-value of 1. Confidence 
intervals can be constructed by the Wald statistic using the estimated variance or with a test-based 
method. The test-based 95% CI for ψ is constructed using those values of ψ in which the g-test fails 
to reject at the 5 percent level. By separately examining exposure status at each time interval, g-
estimation succeeds in controlling for confounding by intermediate variables. 
 
Assumptions of marginal structural models  
For the marginal structural model to estimate the causal effect of non-adherence on clinical 
outcomes, the following assumptions must be true: 1) consistency, 2) exchangeability, 3) positivity, 
and 4) no model misspecification [11].  
Consistency is informally that a subject’s counterfactual (or unobserved) outcome under his 
observed exposure history is equal to his observed outcome. When estimating the effect of medical 
treatments, it is reasonable to assume that consistency holds.  
The second assumption requires that, within the strata defined by all measured covariates, the 
exposure group is randomized.  In other words, the individuals in each exposure group are 
comparable (i.e., exchangeable) given the measured covariates and therefore representative of the 
study population. This assumption is called exchangeability, the sequential randomization 
assumption or the assumption of no unmeasured confounders. This is not a testable assumption and 
relies on the knowledge of the investigator.  
Marginal structural models also rely on the assumption that one is not able to perfectly predict the 
assignment of the intervention given the predictors.  In other words, each subject must have some 
positive probability of non-adhering to their cART regimen, regardless of his or her covariate values. 
This condition is called positivity or the experimental treatment assumption (ETA).  If there is a 
probability of zero in a level of a confounder that is random rather than structural (when it is 
impossible to be exposed at a certain covariate level), parametric models can smooth over these 
random zeros by borrowing information from individuals with similar covariate histories [11, 13]. 
Violation of this assumption will lead to weights with a mean far from one or extreme values. The 
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magnitude of the nonpositivity bias increases with the number of confounders and time points but 
decreases with the use of stabilized weights which are discussed in Chapter 8. 
Marginal structural model requires fitting several models: 1) the final structural model, 2) the model 
to adjust for confounding bias, and 3) the model to adjust for selection or censoring bias. Each of 
these models must be correctly specified. A necessary condition for correct model specification is 
that the stabilized weights have a mean of one at each time point [14].  
 
Comparison of causal models  
IPTW estimators are the most commonly used estimator in practice. However, these models rely 
heavily on the assumptions listed above. Specifically, if the ETA assumption is violated, the IPTW 
estimator can be biased. G-estimators, however, can still be used to consistently estimate the model 
parameters if the ETA assumption is violated but they depend heavily on extrapolation, which relies 
on parametric modeling assumptions instead of real information in the data [2, 10].  
IPTW allows for effect modification by baseline covariates but not time-updated covariates. 
Structured nested models (SNM) using g-estimation were specifically designed to overcome this 
difficulty and are especially useful when evaluating dynamic treatment regimens where treatment 
on a given month is decided partly based on a subject’s covariate history. However with complex 
models, g-estimation may not converge resulting in no single point estimate. In addition, if the 
algorithm converges, a local maximum is found but there is no guarantee that this is a unique 
solution. In addition, SNMs for binary outcomes cannot be fit with g-estimation unless the outcome 
is rare [15]. 
In the next chapter, marginal structural models using IPTW are applied to address the question of 
the causal effect of non-adherence on clinical outcomes. Causal modeling has yet to be utilized in 
the context of adherence and represents a novel approach in the field of adherence research.  
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Chapter 8: Causal effect of non-adherence on clinical outcomes 
 
Marginal structural models to estimate the causal effect of non-adherence on  
clinical outcomes in HIV-infected individuals in the Swiss HIV Cohort Study (SHCS) 
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Introduction  
A limited number of studies have examined the relationship between non-adherence to combined 
antiretroviral therapy (cART) and progression to AIDS or death [1-5].  The findings of these studies 
are difficult to interpret due to confounders such as more advanced stages of HIV infection (lower 
CD4 cell counts at the start of cART), baseline HIV-1 RNA, type of cART (mono, dual, or triple 
therapy), year of initiation of therapy, and depression. The association between non-adherence and 
viral rebound has been studied extensively and confounders of this relationship include injecting 
drug use (IDU), class of cART, length of viral suppression, and physician experience [6-15]. Studies 
addressing both mortality and viral rebound, however, all have methodological limitations; either no 
adjustment for confounding or used only standard statistical models to adjust for confounding which 
can result in biased effect estimates. No studies to date on adherence and clinical outcomes have 
adjusted for confounding by indication – the presence of time-dependent covariates that are 
simultaneously confounders and intermediate variables. Marginal structural models can be used to 
estimate the causal effect of non-adherence on clinical outcomes when there exists confounding by 
indication.     
We used data from the Swiss HIV Cohort Study (SHCS) to estimate the causal impact of non-
adherence to cART on viral rebound and all-cause mortality in naïve patients starting cART and 
compared these results to those from standard statistical models. 
 
Study Description 
Study population 
This longitudinal study was based on prospectively collected data from HIV-infected individuals 
registered in the SHCS. Eligible individuals were antiretroviral naïve and initiated cART between 
January 1, 2003 and June 1, 2009, and completed at least one SHCS adherence questionnaire (SHCS-
AQ) prior to December 1, 2009. Baseline was the date of cART initiation. Follow-up continued until 
the outcome was observed, the individual was lost to follow-up (>12 months since their last visit), or 
December 1, 2009, whichever came first. Additionally, in the model for viral rebound, individuals 
were censored if they discontinued cART for >7 days. Individuals were not censored for treatment 
discontinuation in the model for mortality. If most patients stopped therapy due to toxicity, then it is 
the intention-to-treat effect that is the causal estimate of public health interest. Follow-up of 
participants missing any time-dependent covariate at baseline is started at the first subsequent visit 
at which the values were observed.  
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Outcome 
The study had two primary outcomes: all-cause mortality and viral rebound. Viral rebound which 
was defined as the first HIV-1 RNA viral load >400 copies/ml after either achieving viral suppression 
or being on therapy for at least 6 months.  
Exposure 
The main predictor was self-reported adherence to cART as measured by the SHCS-AQ, which has 
been described elsewhere [6, 16]. In brief, individuals are asked how often they missed a dose of 
cART in the previous four weeks (none, once a month, once every 2 weeks, once a week, more than 
once a week, and every day). We collapsed the last 3 categories of the question on missed doses to 
define non-adherence as missing 0, 1, 2, or >2 doses of cART in the last 4 weeks. In previous work 
using standard Cox models, this definition of non-adherence has been shown to be associated with 
viral rebound [6].  In order to avoid trying to model countless variations of possible exposure 
histories, we modelled the impact of recent adherence on outcome after adjusting for past 
adherence, defined as missed doses on the previous visit. We assumed that once we adjusted for 
prior adherence, an individual’s current adherence was no longer dependent on their history of 
adherence.  
Covariates  
The following baseline confounders of the relationship between non-adherence and clinical 
outcomes were included in the model: age, gender, basic education, ethnicity, prior or current IDU, 
AIDS-defining illness, CD4 cell count (<200, 200-349, 350-499 ≥500 per μL), HIV-1 viral load (<50, 50-
399, ≥400 copies/ml), class of cART (non-nucleoside reverse transcriptase inhibitors (NNRTI), 
ritonavir boosted and unboosted protease inhibitors (PI), triple nucleoside/other), time since HIV 
diagnosis, and experience of the treating physician (estimated by number of SHCS patients seen by 
the physician at time of individual’s baseline visit).  
The time-dependent covariates for the model of mortality include most recently available 
information prior to the exposure: injecting drug use (IDU), CD4 cell count, HIV-1 viral load, class of 
cART, living alone, having a stable partner, and psychological problems (seeing a psychiatrist, 
diagnosis of depression or taking anti-depressants). For the outcome of treatment failure, viral load 
after baseline was not included as it defines the outcome.  Additionally, the time-dependent variable 
of length of time virally suppressed at each visit was included.  
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Data set and model parameterization 
Data points were constructed by dividing up time into person-months of observation with most 
individuals contributing more than one data point. Each data point has an indicator for the exposure, 
the outcome, and a set of covariates. We used the same parameterization described by Hernan, 
Brumback and Robins [17, 18]. We defined T to be the subject’s time until death measured in 
months starting with their initiation of cART. We denoted A(t) to be a subject’s adherence to cART at 
time t. Overbars were used to represent the history of a covariate. So                            
is a subject’s adherence history up to time t. V denotes the vector of time-independent baseline 
covariates measured prior to the start of follow-up. L(t) denotes the vector of time-dependent 
covariates measured at time t. Figure 8.1 gives the directed acyclic graph (DAG) depicting the causal 
structure of the model. Arrows can be interpreted as direct causal effects. 
 
Figure 8.1 Directed acyclic graph of the causal structure for the impact of adherence on mortality  
 
 
 
 
 
 
 
 
 
 
 
 
 
Adherence, A(0) Adherence, A(1) Mortality
Baseline Confounders, V:
Age, Gender, Ethnicity, Education, IDU,  
AIDS, CD4 cell count, HIV-1 RNA, 
class of ART, physician experience, 
time living with HIV
Time-dependent confounders, L(0) :
Class of ART, IDU, CD4, RNA
Time-dependent confounders, L(1):
Class of ART, IDU, CD4, RNA
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Statistical analysis 
The traditional approach to modeling the effect of non-adherence on either mortality or treatment 
failure would be to fit a time-dependent Cox proportional hazards model. The conditional hazard of 
death or treatment failure given non-adherence history and baseline covariates is modeled as 
                                    
If there is unmeasured confounding, this model will provide a biased estimate of the association 
parameter of non-adherence γ1.  However, even if there is no unmeasured confounding, the model 
will provide a biased estimate of the causal effect if there exists time-dependent covariates that are 
simultaneously confounders (associated with both the exposure and the outcome) and intermediate 
variables (on the causal pathway between exposure and outcome). For example, viral load is 
associated with both non-adherence and mortality and is also affected by prior non-adherence.  
Standard regression methods would adjust for the confounder viral load by including it as a covariate 
in the regression model. Intermediate variables, on the other hand, should not be included in 
regression models trying to estimate the total (direct and indirect) causal effect of non-adherence 
and puts the analysis at risk for induced selection bias [19, 20]. 
Marginal structural models allow the estimation of the causal effect of a time-dependent exposure 
in the presence of time-dependent confounders that are also intermediate variables. This is 
accomplished by weighting the analysis so that time-dependent covariates L(t) no longer predicts 
non-adherence at time t. Therefore the parameter γ1 of the weighted Cox model will estimate the 
causal association between recent non-adherence and mortality as in the original study population 
[17].  
Most standard statistical programs do not allow for Cox models with subject-specific weights that 
vary over time. To overcome this, we fit a weighted pooled logistic regression model treating each 
person-month as an observation.  
                                                       
This model is equivalent to a Cox model [21] when the hazard in any single month is small.  
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Estimation of Inverse probability-of-treatment-and-censoring weights 
 Confounding weights 
The conundrum described above - when time-dependent covariates are simultaneously confounders 
(resulting in them being included in the model) and intermediate variables (resulting in them being 
excluded from the model) - can be solved by using time-dependent covariates to calculate the 
weights rather than adding them to the model as regressors. This will allow us to eliminate or reduce 
the bias encountered using standard statistical models. 
To construct the weights to adjust for confounding, we fit two polytomous logistic regression models 
for the probability of non-adherence to obtain their predicted values. The outcome for both models 
returns the relative risk ratio for the non-adherence category compared to the base category.  The 
model returns the relative risk of mortality of missing 1 dose, for example, compared to the base 
category of 0 missed doses. The results of the first model will become the numerator of the weights 
and includes only the time-independent predictors of remaining adherent to cART. This model will 
return the probability of an individual remaining adherent to cART conditional on their adherence 
history and baseline covariates. The second model includes both the time-independent and time-
dependent predictors of remaining adherent to cART. This model will form the denominator of the 
weights and returns the probability of an individual remaining adherent to cART given their previous 
adherence and prognostic factor history. 
The denominator of the weights is providing the bias adjustment and the numerator, which does not 
depend on time-updated covariates, is added for stabilization. By including the model for the 
numerator of the weights in place of 1, we aimed to minimize the difference between the numerator 
and denominator such that the remaining difference reflected only the confounding due to time-
dependent covariates. Stabilized weights generally produce narrower (more efficient) 95% CI that 
have coverage rates closer to 95% [17, 18].  
 Censoring weights 
Similar to the procedure for calculating the confounding weights, two pooled logistic regression 
models were constructed to obtain the predicted values for the probability of remaining 
uncensored. A subject is censored if he or she was lost to follow-up (>12 months since the last visit) 
or reached the administrative end of the study without experiencing the outcome. Additionally, in 
the model for viral rebound, subjects were censored if they discontinued cART for >7 days.  
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The outcome is a censoring indicator C(t) set to 1 if an individual was right-censored at time t and 
C(t)=0 otherwise.  The first model forms the numerator of the weights and includes baseline 
covariates, and adherence. The second model forms the denominator and includes baseline 
covariates, time-dependent covariates, and adherence. 
Stabilized weights 
The product of the stabilized weights for confounding and censoring form the inverse probability-of-
treatment-and-censoring (IPTC) weights used in the final pooled logistic regression model. The 
denominator is informally the probability that an individual has his observed adherence and 
censoring history through month t. Weighting the logistic regression model by the product of these 
two stabilized weights will produce a consistent estimate of the causal effect of non-adherence on 
clinical outcomes assuming the measured covariates are sufficient to adjust for both confounding 
and selection bias due to loss to follow-up.  
Time-dependent intercept  
For our causal estimates of the effect of non-adherence on clinical outcomes to be consistent, it is 
necessary that the denominator of the weights is consistently estimated. To do this, we would need 
to estimate a separate intercept for each month k. However this is not possible so we need to 
borrow strength from other subjects with the same adherence in months other than k to estimate 
the intercept for month k. This can be done by assuming the intercept is a smooth function of the 
time since the beginning of follow-up and can be estimated using smoothing techniques.  We use 
natural cubic splines with 5 knots corresponding to the percentiles 5, 25, 50, 75, and 95 for month 
and add these splines to the models for the weights and the marginal structural model. 
Standard error estimates 
Another difficulty is that the use of weights induces a within-subject correlation that invalidates the 
standard errors produced by standard logistic regression models. Therefore, the weighted logistic 
model should be fit using generalized estimating equations [22, 23] that allow for correlated 
observations and provide robust variance estimators. The corresponding 95% robust Wald 
confidence intervals (CI) will provide a conservative CI for the effect estimate which will cover the 
true estimate 95% of the time in large samples. 
Sensitivity analyses  
In a previous study of individuals starting a new cART regimen, we found that individuals missing one 
dose of cART on a once-daily regimen were more likely to experience treatment failure than those 
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with perfect adherence. However, we did not detect an effect of missing 1 dose in individuals on 
twice daily regimens, suggesting an interaction between dosing frequency and non-adherence [6]. 
To explore if we can replicate these findings in naïve patients using marginal structural models, we 
will stratify by dosing frequency at the time of starting cART.  
For the marginal structural model to estimate the causal effect of non-adherence on clinical 
outcomes, the following assumptions must be true: 1) consistency, 2) exchangeability, 3) positivity, 
and 4) no misspecification of the model [24]. It is reasonable to assume consistency holds in studies 
of medical treatments [25]. The remaining assumptions are either not empirically verifiable [26] or 
computationally intensive [27], however we informally explored how sensitive our estimates were to 
these assumptions.  First, we explored the sensitivity of our causal estimate to the parameterization 
of prior non-adherence. We considered several definitions of past adherence, such as missed doses 
at baseline, missing any doses since baseline, and missed doses on the previous visit. Second, we 
also explored different parameterizations of CD4 cell count and HIV-1 RNA – as categories with 
varying number of categories and as linear terms. With a linear parameterization we added 
restricted cubic splines with either 3 or 5 knots.  This flexible parameterization of time-dependent 
confounders is preferred and can reduce residual confounding or finite-sample bias inherent to 
categorical variables. It can also reduce the potential bias due to model misspecification from strong 
linearity assumptions. Third, we tested for inclusion and exclusion of parameters, such as adding 
lagged variables for CD4 and RNA, including baseline variables for social support and psychological 
problems despite this information being missing for many individuals. Lastly, we explored the effect 
of progressive weight truncation. Specifically, the weights are truncated by resetting the weights 
greater (lower) than the percentile p (1-p) to the value of the percentiles p (1-p). All of these 
sensitivity analyses serve to explore violations of assumptions as well as the tradeoff between bias 
and variance that one must make when attempting to make inferences under these assumptions.  
It was preferred to use stabilized instead of nonstabilized weights in the marginal structural models. 
However, the result of this stabilization means that the weighting creates a pseudopopulation in 
which exposure is randomized only within levels of the baseline covariates. For this reason, the 
baseline covariates must be included in the marginal structural model as there may still be 
confounding due to these variables. The causal effect estimate then assumes the effect is constant 
across levels of the baseline variables. We tested whether this assumption was true by adding 
product (or interaction) terms to the marginal structural model.  For mortality, we tested for effect 
modification of non-adherence within levels of IDU, CD4 category, and class of cART. For viral 
rebound, we considered including product terms for non-adherence and class of cART.   
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Table 8.1 Baseline characteristics of study population for mortality
 
Variable Overall 
N (%) 2422 
Age – median (IQR) 39 (32 – 46) 
Male gender - % 70.6 
Caucasian - %  74.9 
Basic education # - % 26.1 
Risk group for HIV infection % 
    MSM 
    Heterosexual 
    IDU 
    Other 
 
41.3 
44.1 
10.5 
4.2 
Past or current IDU 11.9 
Past or current smoker 61.9 
Past or current psychiatric treatment  15.6 
Living alone 41.7 
Stable partnership 60.9 
HIV-1 RNA viral load (copies/mL) - % 
    < 50 
    50 – 399 
    ≥ 400 
 
2.8 
5.5 
91.7 
CD4 cell count (μ/L) - % 
     < 200 
     200 – 349  
     350 – 499  
     ≥ 500 
 
41.8 
39.9 
11.2 
7.1 
cART regimen  
    NNRTI 
    PI boosted 
    PI non-boosted 
    Triple nucleoside/Other 
 
44.6 
3.0 
48.6 
3.8 
Dosing frequency  
    Once daily 
    Twice daily 
    Three times daily 
 
54.7 
45.1 
0.2 
Taking concomitant medication √ 14.1 
Number of other HIV patients seen by physician 
    Median (IQR)     
 
19 (8 – 50) 
Time since HIV diagnosis (years) 
    Median (IQR) 
 
0.9 (0.1 – 3.9) 
#   9 years of mandatory schooling or less 
√  For opportunistic infections, hepatitis C, cardiovascular risk, or cancer 
IQR=interquartile range, MSM=men who have sex with men, IDU=intravenous drug use, 
cART=combined antiretroviral therapy, NNRTI= non-nucleoside reverse transcriptase inhibitors, 
PI = protease inhibitors 
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Results  
During the almost 7 year study period, 2836 naïve individuals initiated cART.  Of these, 156 (5.5%) 
never completed the SHCS-AQ, 240 (8.5%) did not complete the SHCS-AQ within 1 year of starting 
cART, and 30 (1.1%) did not have any follow-up information on covariates. The final sample included 
2410 individuals with 79,893 person-months of observation.  Individuals were followed for a median 
of 2.7 years (interquartile range (IQR): 1.4 – 4.4). By the end of follow-up, 682 (28.3%) of individuals 
had reported missing one dose, 244 (10.1%) missed 2 doses, and 191 (7.9%) missed >2 doses of cART 
on at least one occasion. There were 242 (10.0%) individuals lost to follow-up and 65 died for a 
crude mortality rate ratio of 2.7 (95% CI: 2.6-2.8).  
Baseline characteristics of included individuals are provided in Table 8.1. For the outcome of viral 
rebound, an additional 260 individuals could not be evaluated for the endpoint. Of the 2150 included 
individuals, 256 (11.9%) individuals were lost to follow-up and 191 (8.9%) experienced viral rebound. 
Baseline characteristics were almost identical to those in the mortality study population (data not 
shown). 
Standard Cox model  
As a first step, standard unweighted time-dependent Cox models were constructed including, at 
each month t, non-adherence A(t), previous non-adherence A(t-1), baseline covariates V, as well as 
the most recent value of the time-dependent covariates, L(t).  In models for all-cause mortality 
including past adherence and a time-dependent intercept, only non-adherent individuals who 
missed >2 doses were at significantly higher risk of death compared to individuals missing 0 doses 
(hazard ratio (HR) 4.01, 95% confidence interval (CI): 1.56 – 10.31) (Table 8.2). While the other effect 
estimates did not change considerably, the association between missing >2 doses of cART and 
mortality increased when adjusting for confounding by baseline variables (HR 5.06, 95% CI: 2.06 – 
12.46) and attenuated when additionally including time-dependent covariates (HR 2.39, 95% CI: 0.79 
– 7.20), as would be expected due to adjusting for time-dependent variables on the causal pathway.  
Similarly, for models of viral rebound, only missing >2 doses of cART was significantly associated with 
a higher risk of treatment failure compared to missing 0 doses (HR 3.80, 95% CI: 1.42 – 10.18). This 
effect was also increased after adjusting for baseline covariates but there was no attenuation after 
adjusting for time-dependent covariates (HR 4.08, 95% CI: 1.47 – 11.38) (Table 8.2). 
Marginal structural model  
To adjust for confounding by indication, we estimated the parameters of marginal structural Cox 
models using stabilized IPTC for each person-month as described above. The marginal structural 
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model included a time-dependent intercept, most recent non-adherence, non-adherence on the 
previous visit, and baseline variables. The estimated causal mortality hazard ratio for missing doses 
of cART compared to missing 0 doses was 0.39 (95% CI: 0.10 – 1.49) for missing 1 dose, 0.30 (95% CI: 
0.04 – 2.44) for missing 2 doses, and 3.88 (95% CI: 1.56 – 9.68) for missing ≥2 doses of cART (Table 
8.2). The causal effect estimates are slightly attenuated compared to the unadjusted associational 
estimate.  
 
Table 8.2: Marginal structural models with inverse probability-of-treatment-and-censoring weights 
for the causal effect of non-adherence to antiretroviral therapy on clinical outcomes 
 
  
 Death Viral rebound 
 HR  95% CI HR  95% CI 
Unweighted estimates † 
  Adjusted for past adherence ‡ 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
   Adjusted for baseline covariates ¶ 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
   Adjusted for baseline & time-varying  
    covariates § 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
 
 
 
0.61 
0.67 
4.01 
 
0.64 
0.74 
5.06 
 
 
0.52 
0.42 
2.39 
 
 
0.19 – 1.97 
0.09 – 4.93 
1.56 – 10.31 
 
0.19 – 2.17 
0.11 – 4.93 
2.06 – 12.46 
 
 
0.17 – 1.61 
0.11 – 1.55 
0.79 – 7.20 
 
 
1.12 
1.46 
3.80 
 
1.16 
1.20 
4.09 
 
 
1.20 
1.14 
4.08 
 
 
0.62 – 2.01 
0.58 – 3.66 
1.42 – 10.18 
 
0.64 – 2.12 
0.43 – 3.35 
1.47 – 11.38 
 
 
0.64 – 2.23 
0.42 – 3.13 
1.47 – 11.38 
Weighted estimates √ 
   Stabilized 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
 
 
 
0.39  
0.30 
3.88 
 
 
0.10 – 1.49 
0.04 – 2.44 
1.56 – 9.68 
 
 
 
1.08 
0.62 
3.63 
 
 
0.53 – 2.19 
0.19 – 2.05 
1.07 – 12.33 
† Unweighted noncausal estimates are shown for comparison purposes only. The unadjusted model includes non-adherence, month, and 
the time-varying intercept. 
‡ Same as model in † with past adherence added – last missed doses and first report of non-adherence (0, 1, 2, >2 doses). 
¶ Models include non-adherence, past non-adherence, and a time-varying intercept as well as the following baseline covariates: age, 
gender, basic education, ethnicity, IDU, AIDS, CD4 (<200, 200-349, 350-499 ≥500 per μL), HIV-1 viral load (<50, 50-399, ≥400 copies/ml), 
class of ART, time since HIV diagnosis, and experience of the treating physician.  
§ Models include variables as described in ¶ plus the most recent value of the following time-varying covariates: IDU, CD4, RNA, class of 
ART, living alone, stable partnership, and psychological problems. NOTE: For the outcome viral load, RNA is not included since this defines 
the outcome. Length of time an individual has maintained viral suppression is added.  
√ Weighted causal estimates from the marginal structural model are calculated as described in text using data on baseline and time-
varying covariates. 
ART=antiretroviral therapy, HR = hazard ratios for the event, CI = confidence intervals, IDU=injecting drug use 
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Table 8.3 Inverse probability-of-treatment-and-censoring estimates of the parameters of a marginal 
structural model for the causal effect of non-adherence on clinical outcomes  
Covariates † Death Viral rebound 
 HR  95% CI HR  95% CI 
Current non-adherence to ART 
   Missing 0 doses 
   Missing 1 dose 
   Missing 2 doses 
   Missing>2 doses 
 
1.0 
0.39  
0.30 
3.88 
 
 
0.10 – 1.49 
0.04 – 2.44 
1.56 – 9.68 
 
 
1.08 
0.62 
3.63 
 
 
0.53 – 2.19 
0.19 – 2.05 
1.07 – 12.33 
Non-adherence at previous visit 
   Missed 0 doses 
   Once a month 
   Every 2 weeks 
   Every week 
   More than once a week 
   Every day 
 
1.0 
2.26 
2.40 
2.69 
13.56 
NE # 
 
 
0.79 – 6.47 
0.27 – 21.22 
 0.47 – 15.25 
4.35 – 42.26  
 
1.0 
1.36 
0.39 
1.41 
1.45 
9.42 
 
 
0.73 – 2.53 
0.05 – 3.05 
0.24 – 8.22 
0.27 – 7.80 
1.30 – 68.36 
Age at baseline, years 1.10 1.07 – 1.14 0.99 0.97 – 1.01 
Male gender 1.42 0.63 – 3.16 1.06 0.66 – 1.68 
Basic Education ¶ 1.08 0.51 – 2.29 1.18 0.73 – 1.91 
Caucasian 0.57 0.17 – 1.95 0.69 0.40 – 1.17 
Past or current IDU 8.86 3.38 – 23.19 1.27 0.68 – 2.40 
AIDS-defining illness 2.08 1.09 – 3.94 0.91 0.56 – 1.47 
Baseline CD4 cell count, per μl 
   <200 
   200 – 349 
   349 – 499 
   ≥ 500 
 
1.0 
1.18 
1.50 
2.44 
 
 
0.60 – 2.31 
0.27 – 8.40 
0.69 – 8.60 
 
1.0 
0.94 
1.04 
2.30 
 
 
0.62 – 1.41 
0.54 – 2.02 
1.14 – 4.64 
Baseline RNA, copies per mL 
   <50 
   50 – 399 
   ≥ 400 
 
1.0 
0.16 
0.49 
 
 
0.01 – 4.74 
0.05 – 4.43 
 
1.0 
0.38 
0.38 
 
 
0.08 – 1.87 
0.14 – 1.02 
Class of ART at baseline 
   NNRTI 
   PI nonboosted 
   PI boosted 
   Triple nucleoside/Other 
 
1.0 
4.07 
2.24 
4.42 
 
 
0.82 – 20.32 
1.09 – 4.59 
1.38 – 14.15 
 
1.0 
1.77 
1.31 
1.41 
 
 
0.62 – 5.05 
0.88 – 1.94 
0.56 – 3.55 
Time since HIV diagnosis, years 0.97 0.91 – 1.03 1.03 0.98 – 1.07 
Experience of treating physician § 0.99 0.93 – 1.06 1.00 0.97 – 1.04 
† Weighted logistic model including a time-dependent intercept (not shown), current non-adherence, prior non-
adherence, and the baseline variables listed in the table. Weights were estimated by swi(t) x swi
†
(t) as defined in the text.   
¶ 9 years of mandatory schooling or less. 
• Number of HIV patients seen by the physician at the individual’s baseline visit. 
# NE = not estimable. Missing doses everyday perfectly predicted failure.  
ART=antiretroviral therapy, HR = hazard ratios for the event, CI = confidence intervals, IDU=injecting drug use, NNRTI=non-
nucleoside reverse transcriptase inhibitor, PI= protease inhibitor 
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The causal estimate of the hazard of viral rebound for those missing doses of cART compared to 
missing 0 doses was 1.08 (95% CI: 0.53 – 2.19) for missing 1 dose,  0.62 (95% CI: 0.19 – 2.05) for 
missing 2 doses, and 3.63 (95% CI: 1.07 – 12.33) for missing ≥2 doses. Again the causal effect is even 
closer to 1 than the unadjusted associational effect.  
The parameter estimates of the marginal structural model are provided in Table 8.3. After adjusting 
for current non-adherence, past non-adherence reported on the previous visit only had a 
significantly negative impact on outcome when the number of missed doses was very high (at least 
once a week).  
Stabilized and nonstabilized IPTC  
The stabilized weights of the marginal structural model for mortality had a mean of 1.02 (standard 
deviation (SD) 0.39) and ranged from 0.005 to 24.36. Estimated weights with a mean far from one or 
extreme values are indications of model violations. As the weights should have a mean of one at 
each time point, we selected the weights at each 6 month interval after baseline and graphed the 
distribution of the log of the stabilized weights (Figure 8.2).The distribution of the non-transformed 
weights is centered at one at each time point and the variation gets smaller with time.  
 
Figure 8.2 Distribution of the stabilized inverse probability-of-treatment-and-censoring weights, SW, 
for the model of mortality.   
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The nonstabilized weights for mortality were extremely large with a mean of 232.14 (SD 3371.56) 
and ranged from 1.04 to 228,557.40 (Figure 8.3). In the pseudopopulation created by the weighting, 
most individuals would be represented by the median weight of 1.29 copies or less of themselves 
but a select few individuals would be represented by over 200,000 copies. The use of stabilized 
weights is critical in this study to increase the efficiency of the analysis so that some individuals are 
not contributing most of the observations in the pseudopopulation. 
The stabilized weights for the marginal structural model for viral load had a mean of 1.00 (standard 
deviation (SD) 0.18) and ranged from 0.03 to 7.50. The distribution of the weights was very similar to 
that for mortality but the range and the variance was smaller. However, the nonstabilized weights 
were even more extreme than the nonstabilized weights for mortality with a mean of 239.45 (SD 
3854.11) and a range from 1.04 to 325,012.80.  
 
Figure 8.3 Distribution of the nonstabilized inverse probability-of-treatment-and-censoring weights, 
SW, for the model of mortality.   
 
Sensitivity analyses 
Stratified analysis 
At baseline, 54.8% of naïve individuals started cART on a once-daily regimen, 45.0% on twice daily 
and only 0.2% were on a three times daily regimen. During the study period, 680 (28.2%) underwent 
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changes to their cART regimen that resulted in a change to their dosing frequency. Of these changes, 
554 (81.5%) were regimen simplifications.  
In stratified marginal structural models, the causal impact of non-adherence to cART on clinical 
outcomes differed depending on baseline dosing frequency (Table 8.4). Individuals starting cART on 
a once-daily regimen had a significantly higher risk of death if they missed >2 doses compared to 
those with missing 0 doses (HR 2.90, 95% CI: 1.09 – 7.72).   The effect of missing 2 doses was not 
estimable as there were very few patients and no deaths in this group. In individuals starting on a 
twice or three times daily regimen, there was no significant causal effect found for missing doses 
compared to perfect adherence. In the models for viral rebound, the causal estimate of the hazard 
of viral rebound for those starting on a once daily regimen and missing doses of cART compared to 
missing 0 doses was 5.49 (95% CI: 1.69 – 17.67) for missing 1 dose, 6.87 (95% CI: 1.07 – 44.01) for 
missing 2 doses, and 9.26 (95% CI: 2.26 – 37.99) for missing ≥2 doses. For those on twice daily or 
three times daily, although the causal effect estimate for missing >2 doses was 2.72, the confidence 
interval was very wide; therefore there was no significant causal effect detected for non-adherence 
and viral rebound.  
 
 
Model assumptions 
We performed several sensitivity analyses to explore the effect of the model assumptions on our 
results. We considered several possible definitions for prior non-adherence including highest past 
reported missed doses, first reported missed doses, and any past missed doses, but it did not 
appreciably alter the results.   
We explored several different scenarios for the models to estimate the IPTC weights (Table 8.5).  The 
first model in this table gives the results from the primary analysis presented in Table 8.3. The 
second and third models explore variations in the adjustment for past adherence. We change the 
parameterization of missed doses on the previous visit from 6 categories to 4 due to sparse data. 
This increased the variance and range of the weights and increased the effect estimate.  The third 
model adjusted for first reported non-adherence in addition to missed doses on the previous visit (6 
categories). This did not affect the weights substantially but moved the effect estimate closer to one 
indicating first reported adherence is potentially an effect modifier for recent non-adherence and 
mortality.  The fourth and fifth model includes CD4 and RNA as linear terms adding restricted cubic 
splines with 3 or 5 knots, respectively, so as not to introduce model misspecification from strong 
linearity assumptions. For both models the mean of the weights remained the same but the 
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standard deviation and the range of the weights increased dramatically. Model 6 adds time-lagged 
variables for both CD4 and RNA which does not change the weights substantially or the effect 
estimates for missing 1 or 2 doses. The estimate for missing 2 doses increases in absolute value 
suggesting better control of confounding, but the standard deviation, and therefore the precision, of 
the estimate decreases. Model 7 adds variables for baseline social support and psychological 
problems. Prior to initiation of cART, 26% of patients did not have any information on these 
variables. Including them in the model for the weights decreased the standard deviation of the 
weights significantly. The effect estimates increase for missing 1 dose and missing >2 doses 
suggesting better control of confounding. However, due to a loss of 32% of the observation time, 
there is a substantial loss of precision. The eighth model reduces the number of categories of CD4 
and RNA in an effort to decrease potential bias due to nonpositivity. The result is weights with a 
mean closer to one and a smaller standard deviation.  However the effect estimates and variance 
increase substantially.  
 
Table 8.4 Marginal structural models with inverse probability-of-treatment-and-censoring weights 
for the causal effect of non-adherence to antiretroviral therapy on clinical outcomes stratified by 
dosing frequency* 
 
 
 Death Viral rebound 
 HR  95% CI HR  95% CI 
Stabilized weighted estimates stratified 
by dosing frequency at baseline √ 
   Once daily 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
   Twice daily or more 
        Missing 1 dose 
        Missing 2 doses 
        Missing>2 doses 
 
 
 
 
0.29 
NE # 
2.90 
 
0.63 
0.44 
0.99 
 
 
 
0.02 – 3.37 
- 
1.09 – 7.72 
 
0.13 – 3.06 
0.04 – 5.15 
0.25 – 4.00 
 
 
 
5.46 
6.87 
9.26 
 
0.85 
0.25 
2.72 
 
 
 
1.69 – 17.67 
1.07 – 44.01 
2.26 – 37.99 
 
0.38 – 1.91 
0.06 – 1.12 
0.56 – 13.25 
* Non-adherence is defined as missing 0, 1, 2, or >2 doses of antiretroviral therapy.  Missing 0 doses is the comparison or reference group. 
Weighted causal estimates from the marginal structural model are calculated as described in text using data on baseline and time-varying 
covariates. Models include non-adherence, past non-adherence, and a time-varying intercept as well as the following baseline covariates: 
age, gender, basic education, ethnicity, IDU, AIDS, CD4 (<200, 200-349, 350-499 ≥500 per μL), HIV-1 viral load (<50, 50-399, ≥400 
copies/ml), class of ART, time since HIV diagnosis, and experience of the treating physician. The following time-varying covariates were 
also included: IDU, CD4, RNA, class of ART, living alone, stable partnership, and psychological problems. NOTE: For the outcome viral load, 
time-varying RNA is not included since this defines the outcome. A time-dependent variable of the length of time an individual has 
maintained viral suppression was also included.  
√ At baseline, 55% of patients were on once daily regimens, 45% on twice daily, and only 0.2% on three or more times daily regimens. 
# NE= not estimable. Due to sparse data, it was not possible to estimate the effect of missing 2 doses in this sub sample. 
HR = hazard ratios for the event, CI = confidence intervals, ART=antiretroviral therapy, IDU=injecting drug use 
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Table 8.5 Effect of non-adherence to antiretroviral therapy on mortality under a series of models for 
the construction of the inverse probability-of-treatment-and-censoring weights * 
 Description Estimated weights Estimate 
  Mean 
(SD) 
Minimum/ 
Maximum 
HR  SE † 
1 Marginal structural model †  
1.02 
(0.39) 
 
0.005 / 24.36 
1 dose           0.39 
2 doses         0.30 
   >2 doses        3.88 
0.27 
0.32 
1.81 
2 Changed definition of past non-
adherence to 0, 1, 2, and >2 missed 
doses  
 
1.02 
(0.50) 
 
0.005 / 41.54 
1 dose           0.46 
2 doses         0.35 
   >2 doses        4.37 
0.30 
0.37 
1.96 
3 Add baseline self-reported 
adherence to model  
 
 
1.02 
(0.41) 
 
0.004 / 31.10 
1 dose           0.37 
2 doses         0.61 
   >2 doses        2.68 
0.25 
0.52 
1.28 
4 Change baseline and time-varying 
CD4 and RNA to linear terms with 3 
knot splines 
 
1.02 
(0.56) 
 
0.002 / 99.35 
1 dose           0.33 
2 doses         0.63 
     >2 doses      3.66 
0.26 
0.63 
3.66 
5 Change baseline and time-varying 
CD4 and RNA to linear terms with 5 
knot splines 
 
1.02 
(0.55) 
 
0.003 / 97.71 
1 dose           0.32 
2 doses         0.51 
     >2 doses      2.96 
0.24 
0.48 
1.41 
6 Add time-lagged variables for time-
varying CD4 and RNA 
 
1.02 
(0.39) 
 
0.005 / 23.91 
1 dose           0.40 
2 doses         0.28 
   >2 doses        4.21 
0.28 
0.31 
2.16 
7 Adding baseline variables for stable 
partnership, living alone, and 
psychological problems 
 
1.02 
(0.16) 
 
0.11 / 23.98 
1 dose           0.52 
2 doses         0.17 
   >2 doses        7.87 
0.37 
0.18 
5.05 
8 Reduce the number of categories 
for CD4 and RNA were reduced ‡ 
 
1.01 
(0.34) 
 
0.005 / 22.45 
1 dose           0.57 
2 doses         0.36 
     >2 doses       7.88 
0.42 
0.39 
5.80 
*Non-adherence is defined as missing 0, 1, 2, or >2 doses of antiretroviral therapy.  Missing 0 doses is the comparison or 
reference group. Past non-adherence is defined as missing doses: never, once a moth, once every 2 weeks, once a week, more 
than once a week, and every day. Each model starts with Model 1 and then implements changes described. 
† This is the weighted marginal structural model as defined in the text and Table 8.3 
‡ CD4 was categorized as: <200, 200-499 ≥500 per μL. HIV-1 viral load was categorized as: <399, ≥400 copies/mL 
 
 
We explored the bias-variance tradeoff in another simple way by progressively truncating the 
weights [28] as described in the methods section. The first row of Table 8.6 corresponds to the 
marginal structural model presented in Table 8.3 while the last row of the table is equivalent to the 
unweighted baseline adjusted model. Assuming the marginal structural model estimate is correct; 
one can see how the bias is increasing (estimates moving toward the estimate from the unweighted 
model) with progressive truncation. In addition, the precision is also decreasing. Therefore, the 
causal effect estimate from the marginal structural model is potentially an improvement in both bias 
and precision from the unweighted model.  
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We were unable to detect any effect modification by baseline covariates in our marginal structural 
model.  However, due to sparse events, some product terms were not able to be estimated and 
therefore we lacked the power to address this issue satisfactorily.  
 
 
Table 8.6 Effect of non-adherence to antiretroviral therapy on mortality under progressive 
truncation of inverse probability-of-treatment-and-censoring weights *  
 
Truncation percentiles Estimated weights Estimate 
 Mean (SD) Minimum/ 
Maximum 
HR  SE † 
    
0, 100 ‡ 
 
 
1.02 (0.39) 
 
0.005 / 24.36 
1 dose           0.39 
2 doses         0.30 
      >2 doses         3.88 
0.27 
0.32 
1.81 
    
1, 99 
 
 
1.00 (0.15) 
 
0.46 / 1.90 
1 dose           0.45 
2 doses         0.35 
      >2 doses         4.43 
0.29 
0.37 
2.05 
   
 5, 95 
         
 
1.00 (0.07) 
 
0.85 / 1.18 
1 dose           0.58 
2 doses         0.66 
      >2 doses         5.35 
0.37 
0.68 
2.55 
    
10, 90 
 
 
1.00 (0.04) 
 
0.93 / 1.08 
1 dose           0.63 
2 doses         0.73 
      >2 doses         5.39 
0.40 
0.75 
2.55 
    
25, 75 
 
 
0.99 (0.02) 
 
0.97 / 1.01 
1 dose           0.67 
2 doses         0.78 
      >2 doses         5.49 
0.43 
0.79 
2.59 
 
50, 50 ‡ 
         
 
0.99 (0.00) 
 
0.99 / 0.99 
1 dose           0.64 
2 doses         0.74 
      >2 doses         5.06 
0.40 
0.71 
2.33 
* Non-adherence is defined as missing 0, 1, 2, or >2 doses of antiretroviral therapy.  Missing 0 doses is the comparison or 
reference group.  
† Robust Wald standard errors 
‡ No truncation corresponds to the estimates of the standard marginal structural model described in the text and setting 
all weights to the 50
th
 percentile corresponds to the standard model adjusted for baseline covariates (see Table 8.2) 
HR = hazard ratios for the event, SD = standard deviation, SE = standard errors  
 
 
 
 
Discussion  
The associational effect of non-adherence to cART on clinical outcomes has been studied in many 
observational settings with varying degrees of methodological rigor. The major limitation of all these 
prior studies has been the lack of proper adjustment for bias. To our knowledge this is the first study 
to use causal modeling methodology to assess the causal impact of non-adherence on treatment 
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failure and mortality. Our results indicate that missing >2 doses of cART results in a more than 3-fold 
increase in the hazard of viral rebound and death. It is difficult to compare our results with previous 
studies due to different measurement methods and definitions of non-adherence. Our effect 
estimate is slightly higher than that reported in earlier studies [1, 2, 5], likely due to adjustment for 
time-dependent confounding, and less precise due to the limited number of events. Standardization 
of adherence measurement and definition is needed to facilitate comparisons across studies.  
The availability of once-daily regimens was met with great enthusiasm and its use has skyrocketed 
over the last years. At the start of our study in 2003, 93.5% of naïve individuals initiated cART on a 
twice-daily regimen. Over the last 7 years this rate has declined steadily and in 2009 only 15.4% of 
patients initiated cART on a twice-daily regimen. We detected an interaction between dosing 
frequency and non-adherence indicating missing doses on a once-daily regimen comes with higher 
consequences than missing doses on a twice-daily regimen. We were not able to detect any effect of 
missing doses on either mortality or viral rebound in those on twice-daily regimens.  On the other 
hand, individuals missing >2 doses of cART on a once-daily regimen had a significantly higher risk of 
mortality. There was a clear dose-response relationship between missed doses and viral rebound in 
those on once-daily regimens with each missed dose causing a significant increased risk of treatment 
failure.  
The present results should be interpreted within the context of the following limitations. Like all 
observational studies, the effect estimates have a causal interpretation only if there is no 
unmeasured confounding. Due to the rich data collection of the SHCS, we were able to include many 
important confounders of the relationship between adherence and clinical outcomes. We did many 
sensitivity analyses to explore variation in our causal estimate due to model misspecification. We 
found some indication that our causal effect estimate was sensitive to model specification and the 
tradeoff between confounding control and efficiency could be substantial. This analysis should be 
repeated in a larger population to further explore the stability of the effect estimates. The results of 
the different sensitivity analyses did not, however, change the substantive conclusions from our 
analysis. Marginal structural models are sensitive to model misspecification, especially in the 
construction of the weights. It would be of interest to compare these results to analyses using g-
estimation of structural nested models (SNM). These models have the advantage that they are not 
as sensitive to model misspecification and can estimate effect modification by time-dependent 
confounders. Development of SNM and comparison of results with marginal structural models is the 
subject of future work. 
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The adherence questions were collected via interview with the patient during their semi-annual 
clinic visit.  This form of data collection could lead to an overestimate of their adherence due to poor 
recall or unwillingness to admit undesirable behavior to their clinician. Despite this potential bias of 
the estimate towards the null, with two simple self-report questions we were able to detect a 
significant effect of missed doses on clinical outcomes.   
Our results present a novel approach to adherence research and our findings draw a spotlight on the 
issue of regimen complexity, in particular the harmful consequences of missing doses after starting 
on a once-daily regimen. Due to the increasing use of once-daily regimens, clinicians should consider 
carefully which dosing frequency suits their patients best. An additional validation of these findings 
in a larger dataset and other patient populations is warranted. 
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Future work 
Additional causal modeling 
There are several different estimators for causal models [1], as discussed briefly in Chapter 7. The 
analysis in Chapter 8 focused only on marginal structural models using IPTC estimators. I would like 
to explore the sensitivity of our results to the choice of estimator used to calculate the weights and 
the type of model. For this reason, it would be of interest to use targeted maximum likelihood 
estimation (TMLE), which targets the maximum likelihood estimate of a parameter in a way that 
reduces bias [2]. This reduction in bias, however, can be accompanied by an increase in the variance 
of the estimate.  
 
Structural nested models (SNM) are another method of causal modelling and can be estimated using 
g-estimation [3, 4], discussed in Chapter 7.  An advantage of using SNF is that one can model the 
interaction of treatment with a time-dependent or time updated covariate, which is a not possible 
using a marginal structural model. In our study, we considered the effect modification of dosing 
frequency at baseline, but it was not possible to evaluate the effect of this variable after baseline. 
SNM would allow us to explore this very important time-updated confounder and its effect on time-
updated adherence. 
  
History-adjusted marginal structural models (HA-MSM) are a generalization of marginal structural 
models and an alternative to SNM. They can be estimated using IPTW or TMLE [5].  A standard 
marginal structural model is assumed at each time point and covariates and treatment history up to 
that time point are treated as baseline data. The output of the HA-MSM is then the causal effect of 
exposure at that time point. These models have been criticized suggesting that they can produce 
logically incompatible parameter estimates therefore resulting in contradictory substantive 
conclusions [6].   
 
Prediction models  
One of the remaining gaps in adherence research is the availability of effective prediction models for 
at-risk patients with respect to non-adherence and therefore worse clinical outcomes. The trajectory 
analysis presented in Chapter 5 provided a novel way to explore patterns in adherence behavior.  
The resulting groups were both distinct and intuitive. I explored these models further with respect to 
clinical outcomes to see if they could provide some sort of framework for constructing prediction 
models.  I repeated the trajectory analysis in the naïve population described in Chapter 8.  As we had 
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already performed this analysis in a naïve (although slightly different) population, it was not 
surprising that the patterns identified by the trajectory analysis were similar (Figure 1). 
 
Figure 1: Trajectories with 95% confidence intervals of adherence groups identified by clustering the 
number of missed doses over time in naïve patients initiating ART after January 1, 2003: group 1 = 
steadily improving adherence group, group 2 = steadily worsening adherence group, group 3 = 
consistently good adherence group, and group 4 = consistently poor adherence group. The predicted 
probabilities of group membership are given. 
 
 
 
I then took these group assignments to see how well they could predict mortality.  The death rate 
was double in the groups who started with missing doses (groups 1 and 4) compared to those 
starting with near perfect adherence (groups 2 and 3) (group 1 = 5.19%, group 4 = 5.43%, group 2 = 
1.74%, and group 3 = 2.32%).  This provided the motivation to explore the role of initial adherence 
on outcome comparing mortality rates by first self-reported non-adherence (0, 1, 2, >2 doses). Again 
there was an increase in the percentage of deaths with more missed doses (0 missed doses = 2.48%, 
1 missed dose = 3.31%, 2 missed doses = 0%, and missing >2 doses = 12.77%), although the category 
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of missing 2 doses did not fit this pattern likely due to sparse data.   This exploration led to adding a 
variable for first reported measure of adherence to the marginal structural models presented in 
Chapter 8.  The result was that first reports of adherence are predictive of both future adherence 
behavior and clinical outcomes. 
Similarly, with the outcome viral rebound, there was a difference in rates of viral rebound by group 
membership. The group with consistently good adherence has a rebound rate of only 6.4% 
compared to 11.43% in those with steadily worsening adherence, 13.11% in those with steadily 
improving adherence and 14.74% in those with consistently poor adherence. The trend in viral 
failure by first reported non-adherence showed a clear dose-response relationship (0 missed doses = 
8.17%, 1 missed dose = 8.82%, 2 missed doses = 17.86%, and missing >2 doses = 37.50%), although 
the difference between 0 and 1 missed dose was minimal.  
The next step of interest would be to develop a prediction model for future adherence behavior. A 
model could be built to predict membership in one of the groups identified by the trajectory analysis 
above including important baseline variables and first adherence report. This model could then be 
cross-validated on other populations or within the data from the SHCS by splitting the data into a 
training and validation set. A validated model would be helpful in daily clinical practice as an 
indicator of what type of adherence support an individual is likely to need in the future. 
 
Resistance 
Resistance is a key issue in the understanding of the relationship between adherence and clinical 
outcomes.  Other researchers have shown that the adherence-resistance relationship is different for 
classes of ART. However, this has yet to be explored in the SHCS or using causal modelling and would 
give a fuller picture of the relationship between adherence and outcomes. 
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Conclusions 
Despite advances in therapy for HIV-infected individuals, non-adherence to combined antiretroviral 
therapy (cART) remains one of the biggest obstacles to successful treatment. The Swiss HIV Cohort 
Study (SHCS) provided a rich framework with which to study the mechanisms impacting adherence 
and the consequences of non-adherence to cART.  
Although more focus has been placed on adherence research in the last decade, universal measures 
and definitions of adherence are still lacking. Adherence support has also not been fully integrated 
into the clinical management of HIV patients and very little data exists about successful and 
sustainable adherence interventions. Future adherence research would benefit from a 
standardization of adherence definitions and measurements. 
The continuous collection of adherence data as well as other psychosocial and clinical data allowed 
for a comprehensive analysis of longitudinal patterns of adherence behavior. We were able to show 
how life events - such as moving house or city, or bouts of depression or increased alcohol intake - 
can quickly result in adherence problems. The future development of a prediction model for 
adherence patterns and clinical outcomes would provide a simple tool for clinicians working with HIV 
patients initiating cART. This together with the knowledge of risk factors for changes in adherence 
could help clinicians to enhance the care they provided to patients.  
The finding that the effect of adherence is mediated by dosing frequency is new and has important 
clinical implications.  Together with the observed increasing trend for individuals to start cART with 
once daily regimens, this result should be carefully considered by clinicians and patients when 
preparing to choose a first regimen.  
These results provide a validation of the effectiveness of a simple self-report questionnaire as a 
causal predictor of clinical outcomes. I hope that these findings will have an impact beyond 
Switzerland by providing a feasible approach to future adherence research. In particular, in resource-
limited settings where it is not possible to measure viral load, a practical measurement tool that is 
easy to implement and at the same time provides a sensitive measure of clinical outcomes would be 
extremely valuable. 
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